<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Trends Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Trends Biotechnol</journal-id><journal-id journal-id-type="pmc-domain-id">445</journal-id><journal-id journal-id-type="pmc-domain">elsevierwt</journal-id><journal-title-group><journal-title>Trends in Biotechnology</journal-title></journal-title-group><issn pub-type="ppub">0167-7799</issn><issn pub-type="epub">1879-3096</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier Sponsored Documents</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10439010</article-id><article-id pub-id-type="pmcid-ver">PMC10439010.1</article-id><article-id pub-id-type="pmcaid">10439010</article-id><article-id pub-id-type="pmcaiid">10439010</article-id><article-id pub-id-type="pmid">35450779</article-id><article-id pub-id-type="doi">10.1016/j.tibtech.2022.03.011</article-id><article-id pub-id-type="pii">S0167-7799(22)00079-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Nano toolbox in immune modulation and nanovaccines</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Azharuddin</surname><given-names initials="M">Mohammad</given-names></name><xref rid="af0005" ref-type="aff">1</xref><xref rid="fn0005" ref-type="fn">4</xref><xref rid="fn0010" ref-type="fn">5</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Zhu</surname><given-names initials="GH">Geyunjian Harry</given-names></name><xref rid="af0010" ref-type="aff">2</xref><xref rid="fn0005" ref-type="fn">4</xref></contrib><contrib contrib-type="author" id="au0015"><name name-style="western"><surname>Sengupta</surname><given-names initials="A">Anirban</given-names></name><xref rid="af0005" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au0020"><name name-style="western"><surname>Hinkula</surname><given-names initials="J">Jorma</given-names></name><xref rid="af0005" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au0025"><name name-style="western"><surname>Slater</surname><given-names initials="NKH">Nigel K.H.</given-names></name><xref rid="af0010" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au0030"><name name-style="western"><surname>Patra</surname><given-names initials="HK">Hirak K.</given-names></name><email>hirak.patra@ucl.ac.uk</email><xref rid="af0015" ref-type="aff">3</xref><xref rid="cr0005" ref-type="corresp">&#8270;</xref><xref rid="fn0015" ref-type="fn">@</xref></contrib><aff id="af0005"><label>1</label>Department of Biomedical and Clinical Sciences (BKV), Link&#246;ping University, Link&#246;ping, Sweden</aff><aff id="af0010"><label>2</label>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK</aff><aff id="af0015"><label>3</label>Department of Surgical Biotechnology, University College London, London, UK</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#8270;</label>Correspondence: <email>hirak.patra@ucl.ac.uk</email></corresp><fn id="fn0005"><label>4</label><p id="np0010">Equal contributions.</p></fn><fn id="fn0010"><label>5</label><p id="np0015">Present address: Cambridge Display Technology, Godmanchester, UK.</p></fn><fn id="fn0015"><label>@</label><p id="np0020">Twitter: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://twitter.com/@Hirak_Nanoscale" id="ir0010">@Hirak_Nanoscale</ext-link></p></fn></author-notes><pub-date pub-type="ppub"><month>10</month><year>2022</year></pub-date><volume>40</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">443619</issue-id><fpage>1195</fpage><lpage>1212</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>20</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-03 18:26:03.153"><day>03</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 The Author(s)</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0005"><p>Despite the great success of vaccines over two centuries, the conventional strategy is based on attenuated/altered microorganisms. However, this is not effective for all microbes and often fails to elicit a protective immune response, and sometimes poses unexpected safety risks. The expanding nano toolbox may overcome some of the roadblocks in vaccine development given the plethora of unique nanoparticle (NP)-based platforms that can successfully induce specific immune responses leading to exciting and novel solutions. Nanovaccines necessitate a thorough understanding of the immunostimulatory effect of these nanotools. We present a comprehensive description of strategies in which nanotools have been used to elicit an immune response and provide a perspective on how nanotechnology can lead to future personalized nanovaccines.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><p id="p0050">Nanoscale materials can extend antigen stability, enhance immunogenicity, and improve antigen presentation time in the targeted cell or tissue.</p></list-item><list-item id="li0010"><p id="p0055">The reasons behind the current success of advanced nanoscale vaccine technologies and how they differ from traditional and conventional vaccines in terms of immune modulation are discussed.</p></list-item><list-item id="li0015"><p id="p0060">The capacity and extent of eliciting humoral and cell-mediated immune responses by nanovaccines are reviewed</p></list-item><list-item id="li0020"><p id="p0065">We present a list of all currently FDA-approved nanovaccines and those in clinical trials.</p></list-item><list-item id="li0025"><p id="p0070">An in-depth and rational understanding will be necessary for the development of nanotools for use in future vaccines. We overview the lessons learnt from this potentially transformative nanovaccine development and how they have been used to elicit an immune response, with a focus on the most recent nanovaccines.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>vaccine</kwd><kwd>nano toolbox</kwd><kwd>nanovaccine</kwd><kwd>immune modulation</kwd><kwd>immune response</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><title>Nanoscale improvements to traditional vaccines</title><p id="p0075">The immune system is an interconnected mesh of cells, tissues, and organs that protect the body against fatal diseases. Immune homeostasis is disrupted by either an underperforming or hyperactive immune response; the former can fail to protect against a simple infection [<xref rid="bb0005" ref-type="bibr">1</xref>] whereas the latter can result in destruction of healthy tissue [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0015" ref-type="bibr">3</xref>]. The immune system consists of innate (non-specific) and adaptive (specific) immunity. Adaptive immunity is characterized by its ability to precisely identify a pathogenic substance and to develop a long-term memory of it. Vaccines train the adaptive immune system to either generate immunological memory before infection (prophylactic) or to recognize ongoing disease (therapeutic) [<xref rid="bb0020" ref-type="bibr">4</xref>]. Although the development of prophylactic vaccines against fatal infections such as smallpox, anthrax, and plague has made a very significant contribution to healthcare, more recent advances in therapeutic vaccines provide promise for treating incurable conditions such as cancer, HIV infection, and type I diabetes [<xref rid="bb0025" ref-type="bibr">5</xref>]. Conventional vaccines based on attenuated or inactivated pathogens suffer from the potential risk of introducing live pathogens and the inability to elicit a satisfactory level of immunity, thus stimulating the development of new vaccines [<xref rid="bb0030" ref-type="bibr">6</xref>]. With progress in nanotechnology, NP-based vaccines (nanovaccines) have been formulated that not only overcome the drawbacks of traditional vaccines but also afford advanced-level modulation that was not previously possible [<xref rid="bb0035" ref-type="bibr">7.</xref>, <xref rid="bb0040" ref-type="bibr">8.</xref>, <xref rid="bb0045" ref-type="bibr">9.</xref>]. Superior efficacy can be achieved by nanovaccines because of (i) extended antigen stability, (ii) enhanced immunogenicity, (iii) targeted delivery, and (iv) sustained release (<xref rid="b0005" ref-type="boxed-text">Box 1</xref>).<boxed-text id="b0005" position="float" orientation="portrait"><label>Box 1</label><caption><title>Key features of nanovaccines</title></caption><p id="p0005"><bold>Extended antigen stability:</bold> because of the protective nature of the NPs, the antigens are protected from degradation by cellular components and enzymes.</p><p id="p0010"><bold>Enhanced immunogenicity:</bold> the NPs themselves can be immunogenic, leading to an enhanced immune response against the target antigen.</p><p id="p0015"><bold>Targeted delivery:</bold> nanovaccines can be designed to deliver antigen to targeted sites such as specific cell types or tissues, and thus reduce the likelihood of harmful side effects.</p><p id="p0020"><bold>Protection of antigens and adjuvants against enzymatic and proteolytic degradation:</bold> key immunogenic components such as peptides, oligonucleotides, and adjuvants are protected from degradation by the nanovaccine formulation.</p><p id="p0025"><bold>Evoke both humoral and cell-mediated immune responses:</bold> the two major branches of immunity (the antibody and cellular responses) can both be enhanced by nanovaccines.</p><p id="p0030"><bold>Present multiple components in a single platform:</bold> multiple antigens can be included in the same NP, leading to a nanovaccine formulation that can potentially protect against a wider range of antigens or infections.</p><p id="p0035"><bold>Enhanced duration of antigen presentation and DC processing:</bold> professional APCs require time to recognize and process antigen before presenting it to elicit a downstream immune response. Nanovaccines can persist for a longer time without alteration or degradation and thereby provide ample opportunity for APCs to boost the immune response.</p><notes notes-type="alt-text" specific-use="for-accessibility" id="al0035"><p>Alt-text: Box 1</p></notes></boxed-text></p><p id="p0080">NPs can provide strong protection to both the antigens and adjuvants against enzymatic and proteolytic degradation [<xref rid="bb0050" ref-type="bibr">10</xref>]. NPs can evoke both humoral and cell-mediated immune responses because of their unique physicochemical characteristics (<xref rid="f0005" ref-type="fig">Figure 1</xref>). They also aid in targeted delivery and can potentially load multiple antigenic components into a single platform [<xref rid="bb0055" ref-type="bibr">11.</xref>, <xref rid="bb0060" ref-type="bibr">12.</xref>, <xref rid="bb0065" ref-type="bibr">13.</xref>, <xref rid="bb0070" ref-type="bibr">14.</xref>, <xref rid="bb0075" ref-type="bibr">15.</xref>, <xref rid="bb0080" ref-type="bibr">16.</xref>]. Lastly, fine-tuning the physical attributes such as size, shape, and surface charge of the NPs can lead to substantial enhancement in the duration of antigen presentation and dendritic cell (DC)-mediated antigen uptake, leading to mature DCs and promoting cell-mediated immunity [<xref rid="bb0085" ref-type="bibr">17.</xref>, <xref rid="bb0090" ref-type="bibr">18.</xref>, <xref rid="bb0095" ref-type="bibr">19.</xref>]. We review how different nanotools have been utilized successfully for improving immunogenicity and developing novel vaccines. The specific role of NPs in vaccine improvement with respect to their size, loading efficiency, nano-enhanced immunogenicity, antigen presentation, and retention in lymph nodes (LNs) is discussed. Finally, nanovaccines that are approved for clinical use or under clinical investigations are summarized.<fig id="f0005" position="float" orientation="portrait"><label>Figure 1</label><caption><p>The basics of nanovaccines and their significance.</p><p>(A) Nanovaccines comprise a selected antigen conjugated to a nanomaterial and an adjuvant to elicit immunogenic response. Multiple antigen epitopes (denoted by red and blue antigens) can be loaded onto the surface of the NPs. Nanomaterial and adjuvant types vary depending on the infection, tissue type, and the immune response required. (B) NPs aid efficient vaccine targeting to the desired cell and its receptors, thereby minimizing side effects. They increase the duration of antigen-receptor engagement and thus enhance the immune response. Specific types of NPs are useful in delivering the antigen into the cytoplasm of the target cell. Packaging of antigens within NPs enhances their protection against enzymatic or proteolytic cleavage. (C) NPs can pass through the lymphatic drainage system and activate APCs within the lymph nodes. (D) NPs aid the DC&#8211;T cell interaction that is necessary to boost the downstream immune response. They activate dendritic cells and influence the release of pro- and anti-inflammatory cytokines. (E) Antibody production by plasma B cells and the differentiation, maturation, and activation of lymphocytes and monocytes is also positively influenced by NP-mediated vaccine delivery. Abbreviations: APC, antigen-presenting cell; DC, dendritic cell; LN, lymph node; NP, nanoparticle; NV, nanovaccine.</p></caption><alt-text id="al0005">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="s0010"><title>Types of nanomaterials</title><p id="p0085">NPs are ideal vehicles to deliver antigens for vaccination because they are comparable in size to viruses and have the ability to load and release active biomolecules [<xref rid="bb0100" ref-type="bibr">20</xref>]. Many types of NPs have been utilized to develop nanovaccines, including metallic NPs, carbon nanotubes, liposomes, micelles, dendrimers, and biomacromolecules. Noble metal NPs, such as colloidal gold, are bio-inert, nontoxic, and their synthesis is well established [<xref rid="bb0105" ref-type="bibr">21</xref>]. Gold NPs (AuNPs) have been utilized for vaccines against influenza [<xref rid="bb0110" ref-type="bibr">22</xref>], malaria [<xref rid="bb0115" ref-type="bibr">23</xref>], and cancer [<xref rid="bb0120" ref-type="bibr">24</xref>]. However, their long-term accumulation remains a safety concern [<xref rid="bb0125" ref-type="bibr">25</xref>]. Other inorganic NPs which have been utilized in vaccine formulations include carbon nanotubes [<xref rid="bb0130" ref-type="bibr">26</xref>], silica NPs [<xref rid="bb0135" ref-type="bibr">27</xref>], and magnetic NPs [<xref rid="bb0140" ref-type="bibr">28</xref>]. Polymeric materials have been widely explored as nanovaccines because of their desirable biodegradability and biocompatibility. Polylactide-co-glycolic acid (PLGA) copolymer [<xref rid="bb0145" ref-type="bibr">29</xref>,<xref rid="bb0150" ref-type="bibr">30</xref>], chitosan [<xref rid="bb0155" ref-type="bibr">31</xref>], and other types of in-house synthesized polymers [<xref rid="bb0160" ref-type="bibr">32.</xref>, <xref rid="bb0165" ref-type="bibr">33.</xref>, <xref rid="bb0170" ref-type="bibr">34.</xref>] have been shown to successfully deliver antigens. Micelles [<xref rid="bb0175" ref-type="bibr">35.</xref>, <xref rid="bb0180" ref-type="bibr">36.</xref>, <xref rid="bb0185" ref-type="bibr">37.</xref>], liposomes [<xref rid="bb0190" ref-type="bibr">38</xref>,<xref rid="bb0195" ref-type="bibr">39</xref>], and dendrimers [<xref rid="bb0200" ref-type="bibr">40</xref>,<xref rid="bb0205" ref-type="bibr">41</xref>] have been investigated as nanovaccines based on their ability to load and deliver antigens. Although proteins usually serve as the antigens in subunit vaccines, engineered proteins can self-assemble into antigen-containing NPs and act as nanovaccines [<xref rid="bb0210" ref-type="bibr">42</xref>,<xref rid="bb0215" ref-type="bibr">43</xref>].</p><p id="p0090">Nanovaccines exploit NP drug delivery systems in general, and biocompatibility and safety are major metrics. Although the goal of nanovaccines is to elicit a specific immune response, it is important that their immunogenicity is antigen-specific rather than NP-specific [<xref rid="bb0220" ref-type="bibr">44</xref>]. By contrast, adjuvanticity &#8211; the ability to augment the immune response &#8211; is desirable for NPs in nanovaccine formulations. It has been demonstrated that NPs made from a wide range of materials can promote an immune response, including those composed of materials that are widely considered to be biocompatible [<xref rid="bb0225" ref-type="bibr">45</xref>]. There is growing evidence that metallic NPs (e.g., gold, iron, and nickel) display immune-modulatory properties by promoting cell recruitment, antigen-presenting cell (APC) activation, and cytokine induction, and can facilitate a humoral response. Niikura and coworkers showed that spherical AuNPs of 40 nm in diameter, surface-modified with West Nile envelope protein (WNE), produced the highest titers of WNE-specific antibodies and also induced inflammatory cytokine production, including tumor necrosis factor-&#945; (TNF-&#945;), interleukin (IL)-6, IL-12, and granulocyte macrophage colony-stimulating factor (GM-CSF) [<xref rid="bb0230" ref-type="bibr">46</xref>]. Citrate-stabilized AuNPs ranging from 2 to 50 nm in diameter conjugated with a synthetic peptide for a foot and mouth disease virus (FMDV) protein showed higher antibody titers for NPs in the 8&#8211;17 nm size range, and other spherical AuNPs (&lt;50 nm) have been reported as antigen carriers for immunization against several other microorganism [<xref rid="bb0110" ref-type="bibr">22</xref>,<xref rid="bb0235" ref-type="bibr">47.</xref>, <xref rid="bb0240" ref-type="bibr">48.</xref>, <xref rid="bb0245" ref-type="bibr">49.</xref>, <xref rid="bb0250" ref-type="bibr">50.</xref>, <xref rid="bb0255" ref-type="bibr">51.</xref>, <xref rid="bb0260" ref-type="bibr">52.</xref>, <xref rid="bb0265" ref-type="bibr">53.</xref>, <xref rid="bb0270" ref-type="bibr">54.</xref>, <xref rid="bb0275" ref-type="bibr">55.</xref>, <xref rid="bb0280" ref-type="bibr">56.</xref>].</p></sec><sec id="s0015"><title>Size-dependent immunogenicity</title><p id="p0095">Antigens delivered by NPs are known to elicit stronger antigenic responses compared to their free counterparts because of the combination of enhanced stability, sustained release, and adjuvant effects [<xref rid="bb0285" ref-type="bibr">57.</xref>, <xref rid="bb0290" ref-type="bibr">58.</xref>, <xref rid="bb0295" ref-type="bibr">59.</xref>]. NP size is a crucial factor that can strongly influence the efficacy and ultimately affects the magnitude and type of immune response (B cell vs. T cell) [<xref rid="bb0300" ref-type="bibr">60</xref>]. Particles with a size of &gt;1 &#956;m (i.e., comparable in size to a bacterial pathogen) are internalized via phagocytosis, whereas smaller particles &lt;1 &#956;m in size are internalized by micropinocytosis, receptor-mediated clathrin-coated endocytosis, and clathrin-independent and caveolin-independent endocytosis [<xref rid="bb0305" ref-type="bibr">61.</xref>, <xref rid="bb0310" ref-type="bibr">62.</xref>, <xref rid="bb0315" ref-type="bibr">63.</xref>]. Thus, particle size is a determining factor that dictates NP entry, the intracellular fate of the antigen processing, and T cell activation. It was recently revealed that small NPs have a higher uptake efficiency by DCs [<xref rid="bb0090" ref-type="bibr">18</xref>,<xref rid="bb0300" ref-type="bibr">60</xref>,<xref rid="bb0320" ref-type="bibr">64</xref>] and accumulate in the LNs with greater efficacy than large NPs, thus inducing an enhanced immune response [<xref rid="bb0325" ref-type="bibr">65</xref>]. However, a universal correlation between size and immune response for solid particle-based NPs has not been reached [<xref rid="bb0330" ref-type="bibr">66</xref>,<xref rid="bb0335" ref-type="bibr">67</xref>], and NPs composed of different core materials showed various optimum sizes for the induction of an immune response [<xref rid="bb0340" ref-type="bibr">68</xref>]. In general, smaller particles are considered to be more effective for targeted drug delivery because of their improved ability to permeate biological barriers [<xref rid="bb0345" ref-type="bibr">69</xref>,<xref rid="bb0350" ref-type="bibr">70</xref>]. Conversely, for a nanovaccine formulation, these criteria do not hold true because the purpose of vaccination is to elicit a designated immune response by allowing specific recognition by the immune system. To date, agreement on the optimum nanovaccine size range that generates a stronger immunological response has not been achieved [<xref rid="bb0320" ref-type="bibr">64</xref>].</p><p id="p0100">For example, 1000 nm bovine serum albumin (BSA)-loaded PLGA particles evoked a more robust serum IgG response than particles sized 200&#8211;500 nm [<xref rid="bb0330" ref-type="bibr">66</xref>]. By contrast, some researchers report that smaller NPs are more efficient and potent immune system stimulators. For instance, an NP-based nicotine vaccine consisting of PLGA and a lipid shell produced a significantly higher anti-nicotine antibody (IgG1 and IgG2) titers with a 100 nm than a 500 nm nanovaccine [<xref rid="bb0355" ref-type="bibr">71</xref>]. One possible explanation is a difference in the mechanism of immunity that is targeted. Large-sized nanomaterials boost humoral immune responses, whereas smaller NPs promote cell-mediated immune protection [<xref rid="bb0360" ref-type="bibr">72.</xref>, <xref rid="bb0365" ref-type="bibr">73.</xref>, <xref rid="bb0370" ref-type="bibr">74.</xref>]. Larger NPs have a tendency to preferentially generate type 2 T helper (Th2) cell responses [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0375" ref-type="bibr">75</xref>,<xref rid="bb0380" ref-type="bibr">76</xref>]. This is mostly because of differential uptake &#8211; for sizes &gt;500 nm the internalization and processing of antigen leads to a more efficient presentation by MHC II, thereby generating a stronger humoral response [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0375" ref-type="bibr">75</xref>]. For example, a study showed that smaller HIV TAT protein-modified cationic polymeric NPs promote a higher TAT-specific cellular immune response and a weaker anti-TAT antibody response than larger particles (~2 &#956;m) [<xref rid="bb0385" ref-type="bibr">77</xref>]. In another study, using poly-lactic acid (PLA)-entrapped hepatitis B virus surface antigen (HBsAg), a single immunization with smaller particles induced a lower humoral response than did larger particles [<xref rid="bb0370" ref-type="bibr">74</xref>]. Immunization with smaller particles encouraged Th1 immune responses, whereas the larger particles favored Th2 responses [<xref rid="bb0370" ref-type="bibr">74</xref>]. This is because the smaller particles were efficiently engulfed by APCs such as macrophages, which leads to cellular immune response, whereas larger particles cannot be taken up by macrophages but can adhere to the macrophage surface and release trapped antigens.</p><p id="p0105">Another study showed that nanobeads of 40&#8211;49 nm could evoke the secretion of Th1-biased cytokines, whereas nanobeads of 93&#8211;101 nm elicited Th2-biased cytokine secretion following immunization in mice [<xref rid="bb0390" ref-type="bibr">78</xref>]. These observations showed that precise selection of NP size for vaccination can influence the type1/type2 cytokine balance, which can be crucial for protection against respiratory syncytial virus [<xref rid="bb0390" ref-type="bibr">78</xref>]. Similarly, polystyrene beads of 40&#8211;50 nm effectively induced cellular responses by activating CD8<sup>+</sup> T cells and interferon (IFN)-&#947; production [<xref rid="bb0395" ref-type="bibr">79</xref>]. This was tested in an <italic toggle="yes">in vivo</italic> animal model where polystyrene beads of 48 nm covalently bound to antigen induced an enhanced antigen-specific Th1-biased response and IFN-&#947; production [<xref rid="bb0400" ref-type="bibr">80</xref>]. Other studies show that NPs of larger size can also induce a robust Th1 response with predominant IFN-&#947; production by priming CD4<sup>+</sup> T cells [<xref rid="bb0405" ref-type="bibr">81</xref>,<xref rid="bb0410" ref-type="bibr">82</xref>]. Researchers have shown that large bile salt-stabilized vesicles (bilosomes) with influenza A antigens elicited immune responses that were biased toward Th1 as compared to small particles [<xref rid="bb0415" ref-type="bibr">83</xref>]. Given such variability, it is difficult to predict the optimum NP size range to elicit a Th1 or a mixed Th1/Th2 immune response. Finally, the kinetics of NP migration through the lymphatic vessels is highly size-dependent [<xref rid="bb0325" ref-type="bibr">65</xref>,<xref rid="bb0420" ref-type="bibr">84</xref>,<xref rid="bb0425" ref-type="bibr">85</xref>]. Particles &lt;5 nm in size can freely enter the bloodstream whereas particles of &gt;100 nm remain at the injection site and fail to move into the lymphatic system. LN targeting is discussed in detail in a later section. <xref rid="t0005" ref-type="table">Table 1</xref> summarizes the size-dependency of nanosystem immunological responses.<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Effect of NP size on the immunological response</p></caption><alt-text id="al0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Size</th><th colspan="1" rowspan="1">Material</th><th colspan="1" rowspan="1">Context</th><th colspan="1" rowspan="1">Immunological response</th><th colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1.5 nm</td><td colspan="1" rowspan="1">Gold</td><td colspan="1" rowspan="1"><italic toggle="yes">Listeria</italic></td><td colspan="1" rowspan="1">AuNP&#8211;LLO (listeriolysin O peptide) plus Advax&#8482; adjuvant induced LLO-specific T cell immunity and protection against <italic toggle="yes">Listeria</italic> challenge</td><td colspan="1" rowspan="1">[<xref rid="bb0235" ref-type="bibr">47</xref>]</td></tr><tr><td colspan="1" rowspan="1">2&#8211;50 nm</td><td colspan="1" rowspan="1">Gold</td><td colspan="1" rowspan="1">Foot and mouth disease</td><td colspan="1" rowspan="1">Specific antibodies were induced by 2, 5, 8, 12, and 17 nm FMDV plus cysteine (pFMDV)&#8211;AuNP conjugates. Maximal antibody titer was generated with 8&#8211;17 nm conjugates</td><td colspan="1" rowspan="1">[<xref rid="bb0240" ref-type="bibr">48</xref>]</td></tr><tr><td colspan="1" rowspan="1">10&#8211;100, 60&#8211;350, 400&#8211;2500 nm</td><td colspan="1" rowspan="1">Bilosome</td><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Larger bilosome particles with influenza A antigens elicited immune responses that had a significantly greater Th1 bias than the small particles</td><td colspan="1" rowspan="1">[<xref rid="bb0415" ref-type="bibr">83</xref>]</td></tr><tr><td colspan="1" rowspan="1">12 nm</td><td colspan="1" rowspan="1">Gold</td><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Matrix 2 protein (M2e)&#8211;AuNP conjugates induced M2e-specific IgG serum antibodies</td><td colspan="1" rowspan="1">[<xref rid="bb0110" ref-type="bibr">22</xref>]</td></tr><tr><td colspan="1" rowspan="1">20&#8211;123 nm</td><td colspan="1" rowspan="1">Polystyrene</td><td colspan="1" rowspan="1">Respiratory syncytial virus (RSV)</td><td colspan="1" rowspan="1">IFN-&#947; induction from CD8 T cells was limited to 40&#8722;49 nm beads, whereas CD4 T cell activation and IL-4 were induced by 93&#8722;123 nm beads</td><td colspan="1" rowspan="1">[<xref rid="bb0390" ref-type="bibr">78</xref>]</td></tr><tr><td colspan="1" rowspan="1">30&#8211;200 nm</td><td colspan="1" rowspan="1">Polystyrene</td><td colspan="1" rowspan="1">Tumor</td><td colspan="1" rowspan="1">Nanobeads of 40&#8211;50 nm effectively induced cellular responses by activating CD8<sup>+</sup> T cells with IFN-&#947; production</td><td colspan="1" rowspan="1">[<xref rid="bb0395" ref-type="bibr">79</xref>]</td></tr><tr><td colspan="1" rowspan="1">40 nm</td><td colspan="1" rowspan="1">Gold</td><td colspan="1" rowspan="1">Tetanus toxoid</td><td colspan="1" rowspan="1">Enhanced tetanus toxoid (TT)-specific IgG (34.53&#215;) and IgA (43.75&#215;) was elicited by TT-ARE-CsAuNPs</td><td colspan="1" rowspan="1">[<xref rid="bb0245" ref-type="bibr">49</xref>]</td></tr><tr><td colspan="1" rowspan="1">100, 500 nm</td><td colspan="1" rowspan="1">PLGA</td><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">The 100 nm particles induced significantly higher antibodies than the 500 nm particles</td><td colspan="1" rowspan="1">[<xref rid="bb0355" ref-type="bibr">71</xref>]</td></tr><tr><td colspan="1" rowspan="1">200, 500, 1000 nm</td><td colspan="1" rowspan="1">PLGA</td><td colspan="1" rowspan="1">Bovine serum albumin</td><td colspan="1" rowspan="1">A greater IgG response was elicited by 1000 nm particle than by 200&#8211;500 nm particles</td><td colspan="1" rowspan="1">[<xref rid="bb0330" ref-type="bibr">66</xref>]</td></tr><tr><td colspan="1" rowspan="1">200&#8211;600 nm, 2&#8211;8 &#956;m</td><td colspan="1" rowspan="1">PLA</td><td colspan="1" rowspan="1">Hepatitis B virus</td><td colspan="1" rowspan="1">Hepatitis B virus surface antigen (HBsAg) encapsulated in 2&#8211;8 &#956;m particles generated more antibodies than 200&#8211;600 nm particles</td><td colspan="1" rowspan="1">[<xref rid="bb0370" ref-type="bibr">74</xref>]</td></tr><tr><td colspan="1" rowspan="1">220, 660, 1990 nm</td><td colspan="1" rowspan="1">PMMA<break/>Eudragit&#174;</td><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">HIV TAT protein modified NPs of 220 or 630 nm elicit strong TAT-specific cellular immune response but weaker anti-TAT antibody response than NPs of 1.99 &#956;m</td><td colspan="1" rowspan="1">[<xref rid="bb0385" ref-type="bibr">77</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="s0020"><title>NP loading of antigens</title><p id="p0110">Antigens of interest can be either encapsulated within or attached to the surface of NPs. Antigen encapsulation can be achieved with polymeric, micellar, and liposomal NPs [<xref rid="bb0430" ref-type="bibr">86</xref>], and surface functionalization can be performed with polymeric, inorganic, or metallic NPs [<xref rid="bb0335" ref-type="bibr">67</xref>,<xref rid="bb0395" ref-type="bibr">79</xref>,<xref rid="bb0435" ref-type="bibr">87</xref>,<xref rid="bb0440" ref-type="bibr">88</xref>]. In general, encapsulation of antigens into NP cores gives protection against enzymatic degradation, whereas surface immobilization mimics the presentation of antigens by pathogens [<xref rid="bb0445" ref-type="bibr">89</xref>]. More recent studies have focused on using biomimetic strategies to load antigens, such as by using lipid membranes. Liu and colleagues reported the fabrication of self-assembled nanovaccines containing phospholipids which were able to deliver strong initial antigen stimulation followed by controlled long-term antigen release, leading to effective cross-presentation and a CD8<sup>+</sup> T cell response [<xref rid="bb0450" ref-type="bibr">90</xref>]. When choosing the loading method, multiple factors including loading capacity, release efficiency, preservation of antigen function and structure, epitope orientation, and the overall influence on the colloidal stability of the NPs [<xref rid="bb0455" ref-type="bibr">91</xref>] must be carefully considered.</p><p id="p0115">To date, there are limited systematic studies on the effect of loading methods on nanovaccine efficiency. One reason is that the loading method is often specific to the NP system of choice, such as surface functional groups, geometry structure, and fabrication technique (<xref rid="f0010" ref-type="fig">Figure 2</xref>). It was found that chemically conjugated protein antigen induced a stronger immune response than when the same antigen was simply physically mixed with the NPs, but this was possibly because of different loading capacities [<xref rid="bb0395" ref-type="bibr">79</xref>]. A study comparing PLGA NPs with encapsulated versus surface-adsorbed ovalbumin (OVA) demonstrated that faster <italic toggle="yes">in vitro</italic> internalization was achieved by the encapsulation architecture; however, the difference might be caused by a change in surface charge [<xref rid="bb0460" ref-type="bibr">92</xref>]. In addition, it was revealed that PLGA NPs with encapsulated OVA preferentially activated the MHC I pathway as compared to PLGA NPs with surface-adsorbed OVA which resulted in enhanced MHC II presentation [<xref rid="bb0460" ref-type="bibr">92</xref>]. Several other reports imply that liposomes with covalently conjugated antigens generate stronger antibody responses than other types of loading strategies [<xref rid="bb0285" ref-type="bibr">57</xref>,<xref rid="bb0465" ref-type="bibr">93.</xref>, <xref rid="bb0470" ref-type="bibr">94.</xref>, <xref rid="bb0475" ref-type="bibr">95.</xref>, <xref rid="bb0480" ref-type="bibr">96.</xref>, <xref rid="bb0485" ref-type="bibr">97.</xref>, <xref rid="bb0490" ref-type="bibr">98.</xref>, <xref rid="bb0495" ref-type="bibr">99.</xref>]. For DNA vaccines, there have been reports that plasmid DNA vaccine adsorbed onto PLGA NPs was much more efficient than the same DNA entrapped inside PLGA [<xref rid="bb0500" ref-type="bibr">100</xref>]. In DNA vaccines, the nanocarriers serve as the non-viral vector for gene delivery (as reviewed extensively elsewhere [<xref rid="bb0505" ref-type="bibr">101</xref>,<xref rid="bb0510" ref-type="bibr">102</xref>]). To sum up, it seems the surface-loading method has some advantages over the entrapment method, but more systematic studies with various nanosystems should be conducted to provide a clearer picture.<fig id="f0010" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Comparative account of loading strategies of nanoparticles to boost the immune response.</p><p>Different modes of loading of the nanomaterials to enhance immune responses. It was previously reported that encapsulation of antigens tends to provide better protection [<xref rid="bb0445" ref-type="bibr">89</xref>], better MHC I activation [<xref rid="bb0460" ref-type="bibr">92</xref>], and better nuclear delivery [<xref rid="bb0500" ref-type="bibr">100</xref>] than surface immobilization. Covalently attached antigens can generate stronger immune responses than non-covalently tethered antigens [<xref rid="bb0395" ref-type="bibr">79</xref>]. Liposomes can elicit stronger antibody responses than other nanoparticle systems [<xref rid="bb0285" ref-type="bibr">57</xref>,<xref rid="bb0465" ref-type="bibr">93.</xref>, <xref rid="bb0470" ref-type="bibr">94.</xref>, <xref rid="bb0475" ref-type="bibr">95.</xref>, <xref rid="bb0480" ref-type="bibr">96.</xref>, <xref rid="bb0485" ref-type="bibr">97.</xref>, <xref rid="bb0490" ref-type="bibr">98.</xref>, <xref rid="bb0495" ref-type="bibr">99.</xref>]. Abbreviations: APC, antigen-presenting cell; OVA, ovalbumin; PLGA, polylactide-co-glycolic acid.</p></caption><alt-text id="al0010">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="s0025"><title>Nano-enhanced immunogenicity and antigen delivery</title><p id="p0120">Antigens delivered by NPs are internalized through several endocytic pathways. Apart from the size effect discussed above, surface charge and surface functionalization of targeting molecules can facilitate delivery to APCs for antigen presentation. Cationic NPs are internalized by APCs more rapidly and usually promote intracellular trafficking through endosomal escape [<xref rid="bb0515" ref-type="bibr">103</xref>]. Cationic dendrimer NPs with adsorbed antigens demonstrate enhanced delivery of antigens to DCs, and simultaneously activate DCs including the secretion of cytokines such as IL-1&#946; and IL-12 [<xref rid="bb0520" ref-type="bibr">104</xref>]. DCs play a crucial role in the orchestration of the innate and adaptive immune system through antigen uptake, processing, and presentation of epitopes to naive T cells (<xref rid="f0015" ref-type="fig">Figure 3</xref>, right). Because most vaccines used in current practice are exogenous to the cells, DCs play a vital role in vaccine-activated cellular immune responses against viral and cancerous diseases. Hence, numerous strategies have been developed for nanovaccine targeting of DCs [<xref rid="bb0350" ref-type="bibr">70</xref>].<fig id="f0015" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Mechanism of action of nanovaccines.</p><p>Different types of antigens conjugated to nanoparticles (NPs) stimulate antigen-presenting cells (APCs) to process and present the antigens in different manners. Some antigens are received by mannose receptors, some are degraded within the APCs and the antigenic peptide fragments are then presented via MHC I (to activate CD8 T cells) or via MHCII (to activate CD4 T cells). APCs (like dendritic cells and T cells) also secrete cytokines in the process. This release of cytokines alters the cytokine milieu and shapes either pro- or anti-inflammatory responses. Clonal expansion of the activated T cells and B cells leads to boosting of the immune response. Activated plasma B cells release antibodies in response to the specific antigen conjugated to the NPs. Some cells remain as memory cells to provide an immediate antibody response in the case of natural antigenic challenge. The annotations adjacent to individual nanovaccines highlight mechanistic steps taking place in APCs or downstream immune response column and illustrate the diverse mechanisms of action of individual nanovaccines. Abbreviation: LPS, lipopolysaccharide.</p></caption><alt-text id="al0015">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0125">DCs express cell-surface mannose receptors which help in antigen internalization through mannosylation, and this enhances the activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses [<xref rid="bb0525" ref-type="bibr">105</xref>]. The same strategy has been employed successfully using a dextran-based nanovaccine with lipopolysaccharide (LPS). Nanoformulations showed robust antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses, and generated stronger CD8<sup>+</sup> T cell response than the soluble antigen and LPS mixture [<xref rid="bb0530" ref-type="bibr">106</xref>]. By targeting the langerins (CD207) which are exclusively expressed on Langerhans cells, liposomes conjugated with langerin ligands exhibited effective targeting of Langerhans cells in human skin [<xref rid="bb0535" ref-type="bibr">107</xref>]. In addition to the usual MHC II presentation and CD4<sup>+</sup> T helper cell activation pathway, DCs can also process antigens and present them via the MHC I pathway leading to activation of CD8<sup>+</sup> T cell response in a process known as 'cross-presentation' [<xref rid="bb0540" ref-type="bibr">108</xref>,<xref rid="bb0545" ref-type="bibr">109</xref>]. This cross-presentation occurs via the cytosolic pathway. The exogenous antigens are processed in the cytosol by proteasomes [<xref rid="bb0545" ref-type="bibr">109</xref>]. Nanovaccines can modulate intracellular antigen delivery and promote cross-presentation. Many types of NPs including inorganic, polymeric, and lipid NPs were shown to induce effective CD8<sup>+</sup> T cell expansion by antigen cross-presentation [<xref rid="bb0550" ref-type="bibr">110</xref>,<xref rid="bb0555" ref-type="bibr">111</xref>]. A specially designed polymeric microneedle with encapsulated antigens was able to target Langerhans cells with efficient cross-priming and Th1 immune responses [<xref rid="bb0560" ref-type="bibr">112</xref>]. Cross-presentation was shown to be dependent on the particle&#8211;antigen linkage, and disulphide bonding between NPs and antigens results in antigen release into the endosomal compartment leading to subsequent CD8<sup>+</sup> T cell expansion, whereas non-degradable linkers do not [<xref rid="bb0565" ref-type="bibr">113</xref>].</p><p id="p0130">Other than the cell-mediated immune response, various nanovaccines can elicit humoral responses. B cells, which oversee antibody production, require prolonged and constant activation to generate humoral responses. As mentioned previously, the strategy for loading the antigens onto the NPs may have a profound influence on the resulting humoral responses. For example, calcium phosphate NPs with the antigen covalently attached to the surface exhibit a substantial increase in B cell activation <italic toggle="yes">in vitro</italic> in comparison to the soluble antigen. Similarly, antigen displayed on the surface of multilamellar vesicles provided an enhanced humoral response compared to the encapsulated antigen. However, studies are few and further exploration is warranted. Elevated levels of antigen-specific antibodies can also be achieved by multivalent presentation of antigens, and NP systems can serve as the platform for this purpose. Ueda and colleagues have engineered self-assembling NPs for tailoring the optimal geometry for multivalent presentation of viral glycoproteins [<xref rid="bb0570" ref-type="bibr">114</xref>].</p></sec><sec id="s0030"><title>Strengthening lymph node retention by nanovaccines</title><p id="p0135">The generation of a cell-mediated immune response relies on efficient trafficking or drainage of antigenic components to LNs for further processing and presentation to T and B cells. LNs thus represent a crucial target site for the delivery of vaccines and other immunotherapeutic agents because direct delivery of antigenic components into APCs residing in LNs can induce more potent and robust immune stimulation than can antigen uptake by migrating APCs. LNs also contain a substantial fraction of resident DCs which are phenotypically immature and well equipped for simultaneously internalizing antigens and particles [<xref rid="bb0575" ref-type="bibr">115</xref>]. By targeting LN APCs or DCs instead of those in peripheral sites, immune tolerance as a result of antigen exposure on the DC surface before reaching the LN can be avoided [<xref rid="bb0580" ref-type="bibr">116</xref>]. In addition, DC-targeting ligands are not a prerequisite because the <italic toggle="yes">in situ</italic> concentration of LN-resident DCs is extremely high [<xref rid="bb0585" ref-type="bibr">117</xref>,<xref rid="bb0590" ref-type="bibr">118</xref>]. Therefore, targeting APCs including DCs in LNs that can be readily taken up into lymphatic vessels and retained in draining LNs is a promising strategy.</p><p id="p0140">As mentioned in the previous section, particle size plays an important role in LN targeting and retention. In one study, a synthetic vaccine NP (SVNP) was developed to improve the targeting and retention efficacy of cancer vaccines [<xref rid="bb0595" ref-type="bibr">119</xref>]. The positively charged SVNPs of varying size upon conjugation with a negatively charged tumor antigen showed rapid migration into LNs, leading to secretion of higher levels of proinflammatory cytokines and type I IFN (IFN-&#945;, IFN-&#946;) [<xref rid="bb0595" ref-type="bibr">119</xref>]. In another study, biodegradable NPs of 20, 45, and 100 nm were used as delivery vehicles to DCs in LNs [<xref rid="bb0420" ref-type="bibr">84</xref>]. It was observed that 20 nm poly(ethylene glycol) (PEG)-stabilized poly(propylene sulfide) (PPS) NPs, which can carry hydrophobic drugs and degrade in an oxidative environment, were taken up readily by lymphatic vessels following interstitial administration with 20 nm and 45 nm particles, and showed enhanced retention in LNs [<xref rid="bb0420" ref-type="bibr">84</xref>]. In another instance, large particles (500&#8211;2000 nm) were shown to be mostly internalized by DCs from the site of injection, whereas particles of 20&#8211;200 nm and virus-like particles (30 nm) were found in LN- resident DCs and macrophages, indicating free drainage and retention of these particles in LNs [<xref rid="bb0600" ref-type="bibr">120</xref>]. It was shown that biodegradable 20 nm PLGA-b-PEG NPs rapidly drained across proximal and distal LNs with a higher retention time than 40 nm particles, whereas the drainage of 100 nm NPs was negligible [<xref rid="bb0605" ref-type="bibr">121</xref>]. In another study where 25 nm and 100 nm Pluronic-stabilized PSS NPs were intradermally injected, there was ten-fold greater interstitial flow into lymphatic capillaries and associated draining LNs for 25 nm particles than for 100 nm particles [<xref rid="bb0325" ref-type="bibr">65</xref>]. Size-dependent LN targeting was also exhibited by 30 nm and 90 nm AuNPs antigen carriers, and 30 nm particles displayed higher LN retention and accumulation than 90 nm particles [<xref rid="bb0610" ref-type="bibr">122</xref>]. In summary, small particle size is required for efficient penetration of lymphatic vessels and prolonged LN retention. NPs with a size in the 20&#8211;200 nm range, which coincides with the sizes of viral particles, can exploit interstitial flow for lymphatic delivery, and in this range smaller NPs tend to accumulate more in the LNs.</p></sec><sec id="s0035"><title>Nanomaterial-mediated inflammation and cytokine release</title><p id="p0145">Nanomaterials are known to boost the immune system and have been used to develop vaccines when conjugated with antigens. We review here cases of inflammation reported in the literature that resulted from inflammatory cytokine release following NP administration. The Th1 or Th2 responses elicited thus caused either an efficient immune response or damage to the host tissue.</p><p id="p0150">The use of a lipid-based particle (ISCOMATRIX) as the adjuvant for a chimeric peptide vaccine containing multiple epitopes of T cell lymphotropic virus (HTLV) type I led to enhanced production of mucosal IgA and IgG2a antibody titers as well as increased IFN-&#947; and IL-10 production [<xref rid="bb0610" ref-type="bibr">122</xref>]. Carbon NPs containing bovine serum albumin exhibited strong stimulation of IgA antibodies in salivary, intestinal, and vaginal mucosa following oral immunization. They were also capable of inducing Th1 and Th2 responses [<xref rid="bb0615" ref-type="bibr">123</xref>]. Kim and coworkers synthesized synthetic vaccine NPs with a combination of OVA and Toll-like receptor 3 (TLR3). These enhanced antigen uptake by APCs and the secretion of inflammatory cytokines including type I interferon, TNF-&#945;, and IL-6 [<xref rid="bb0595" ref-type="bibr">119</xref>]. <italic toggle="yes">Mycobacterium</italic>
<italic toggle="yes">tuberculosis (</italic>MtB) lipids attached to chitosan NPs induce both cell-mediated and humoral immunity leading to enhanced secretion of IgG, IgM, and Th1/Th2 cytokines [<xref rid="bb0615" ref-type="bibr">123</xref>]. Amantadine-coated silver NPs triggered HIV-specific cytotoxic T lymphocyte (CTL) production and eightfold stronger TNF-&#945; production <italic toggle="yes">in vivo</italic> [<xref rid="bb0620" ref-type="bibr">124</xref>].</p><p id="p0155">Multiwalled carbon nanotubes and silica NPs can both activate the NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome leading to uncontrolled pathological inflammation. Superparamagnetic iron oxide NPs (SPIONs) showed enhanced activation of inflammatory genes in response to LPS [<xref rid="bb0625" ref-type="bibr">125</xref>]. The PLGA-OVA<sup>+</sup> A20 nanovaccine maintains immune homeostasis by suppressing Th2 inflammation and promoting the regulatory T cell (Treg) response and IL-10 production in lung airway tissue of an allergic asthma murine model [<xref rid="bb0630" ref-type="bibr">126</xref>].</p><p id="p0160">Synergistic stimulation of the production of IL-1&#946; by some NPs and bacteria induces strong pathological inflammation leading to leukocyte influx, swelling, fever, vasodilation, and inflammation-driven tissue damage [<xref rid="bb0635" ref-type="bibr">127</xref>]. Elevated release of proinflammatory cytokines such as IL-6, TNF-&#945;, IL-12 from APCs was observed after the uptake of DNA-inorganic hybrid nanovaccines (hNVs) [<xref rid="bb0640" ref-type="bibr">128</xref>]. The adjuvants used with NP vaccines such as alum, oil in water emulsions (incomplete Freund's adjuvant), and monophosphoryl lipid A (MPLA) are also sometimes associated with inflammation.</p><p id="p0165">Size-dependent immunogenicity of polystyrene particles carrying CpG oligonucleotides was observed in DCs leading to differential expression of IL-6 and IFN-&#945;. CpG-mediated activation of the MAPK and nuclear factor &#954;B (NF-&#954;B) pathways induced the expression of proinflammatory cytokines (e.g., IL-6, IL-12, and TNF-&#945;) [<xref rid="bb0645" ref-type="bibr">129</xref>]. The Th1 immunostimulatory response thus generated suppressed the Th2 immunoregulatory response [<xref rid="bb0650" ref-type="bibr">130</xref>].</p><p id="p0170">Potential cytotoxicity of CTLs was observed in an overtly activated proinflammatory cytokine (IFN-&#947;, TNF-&#945;) response following albumin/albiCpG nanocomplex inoculation into mice. Encapsulated OVA polyanhydride NPs boosted the formation of antigen-specific CD8<sup>+</sup> T cell memory after vaccination [<xref rid="bb0655" ref-type="bibr">131</xref>]. Subcutaneous delivery of polyanhydride NPs induced only a mild inflammatory response with no tissue damage [<xref rid="bb0660" ref-type="bibr">132</xref>]. Hyperactivation of the inflammatory response impaired the trafficking, maturation, activation, and memory cell formation of CD8<sup>+</sup> T cells [<xref rid="bb0665" ref-type="bibr">133</xref>]. More efficient administration of vaccine (e.g., DC-based vaccines, antigen-coated particle formulations) leading to an absence of overt inflammation induced the formation of memory CD8<sup>+</sup> T cell more effectively following antigen delivery [<xref rid="bb0670" ref-type="bibr">134</xref>].</p></sec><sec id="s0040"><title>Nanovaccines in clinical use and in clinical trials</title><p id="p0175">Only a few nanovaccines have been successfully translated from the laboratory to the clinics. Of these, most only elicit humoral responses, and there is an unmet need for the development of vaccines that can generate strong cellular responses against infectious diseases and cancer. Vaxfectin&#174; is a cationic liposomal nanovaccine which is currently in clinical trials. Vaxfectin&#174; has been used against herpes simplex virus type 2 (HSV-2) and also against influenza virus (H5N1) [<xref rid="bb0675" ref-type="bibr">135</xref>]. Similarly, another FDA-approved nanovaccine, Inflexal&#174;V, has been used as a subunit influenza vaccine in which the hemagglutinin (HA) surface molecules of influenza virus are conjugated to lipid components [<xref rid="bb0680" ref-type="bibr">136</xref>]. Stimulax&#174;, a liposomal therapeutic nanovaccine that is currently under clinical investigation, has been employed as vaccine against cancer [<xref rid="bb0685" ref-type="bibr">137</xref>]. Epaxal is another liposome-based nanovaccine against hepatitis A infection [<xref rid="bb0690" ref-type="bibr">138</xref>].</p><p id="p0180">Significant attention to NPs has been recently drawn during the development of effective vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (<xref rid="f0020" ref-type="fig">Figure 4</xref>). Synchronized innate and adaptive (both humoral and cell-mediated) immune responses are essential for achieving virus clearance from the host. The use of NPs to achieve this goal is generally essential, and a list of SARS-CoV-2 vaccines that take advantage of nanomaterials is provided in <xref rid="t0010" ref-type="table">Table 2</xref>.<fig id="f0020" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Strategies for the development of nanovaccines against SARS-CoV-2.</p><p>(A) The spike protein S that is present at the surface of the virus is unique for SARS-CoV-2 and has been used as a vaccine target by different laboratories. Nanovaccines comprise S protein mRNA. although the corresponding DNA sequence can also used. S proteins are often broken down into fragments that can also be used as antigens. (B) (i) The Astrazeneca, Sputnik V, and Johnson &amp; Johnson vaccines use conventional adenovirus-mediated DNA transfer method to express SARS-CoV-2 S protein at the site of inoculation. (ii) The Moderna and Pfizer vaccines introduce S mRNA by means of lipid nanoparticles, leading to local synthesis. (iii) Novavax contains S protein embedded in a nanoparticle system, whereas (iv) Bharat Biotech and Sinopharm used a conventional inactivated whole virus vaccine. Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.</p></caption><alt-text id="al0020">Figure 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig><table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Nanovaccines approved or in clinical trials<xref rid="tf0005" ref-type="table-fn">a</xref></p></caption><alt-text id="al0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Organization</th><th colspan="1" rowspan="1">Name of vaccine</th><th colspan="1" rowspan="1">Type of antigen</th><th colspan="1" rowspan="1">Nanomaterial used</th><th colspan="1" rowspan="1">Clinical trial (registration number)</th><th colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Moderna and NIAID</td><td colspan="1" rowspan="1">mRNA-1273 LNP</td><td colspan="1" rowspan="1">mRNA-1273 mRNA</td><td colspan="1" rowspan="1">LNP with mRNA encapsulated</td><td colspan="1" rowspan="1">Phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04283461">NCT04283461</ext-link>)<break/>Phase II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link>)<break/>Phase III (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470427">NCT04470427</ext-link>)</td><td colspan="1" rowspan="1">[<xref rid="bb0695" ref-type="bibr">139</xref>,<xref rid="bb0700" ref-type="bibr">140</xref>]</td></tr><tr><td colspan="1" rowspan="1">BioNTech and Pfizer</td><td colspan="1" rowspan="1">mRNA BNT162b2</td><td colspan="1" rowspan="1">mRNA encoding the trimerized RBD of SARS-CoV-2</td><td colspan="1" rowspan="1">LNP with mRNA encapsulated</td><td colspan="1" rowspan="1">Phase I/II (UTRN U1111-1249-4220)<break/>Phase I/II (Germany) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537949">NCT04537949</ext-link><break/>EudraCT Number (Germany) (2020&#8211;001038-36)<break/>Phase II/III (USA) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link>)<break/>Phase I/II (ChiCTR2000034825)<break/>Phase I (Japan) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04588480">NCT04588480</ext-link></td><td colspan="1" rowspan="1">[<xref rid="bb0705" ref-type="bibr">141</xref>,<xref rid="bb0710" ref-type="bibr">142</xref>]</td></tr><tr><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">NVX-CoV2373</td><td colspan="1" rowspan="1">Full-length SARS-CoV-2 S glycoprotein</td><td colspan="1" rowspan="1">Recombinant glycoprotein NP saponin-based Matrix-M1 adjuvant</td><td colspan="1" rowspan="1">Phase I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link>)<break/>Phase II (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04533399">NCT04533399</ext-link>)<break/>Phase III (UK) (2020&#8211;004123-16)<break/>Phase III (USA/Mexico) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04611802">NCT04611802</ext-link></td><td colspan="1" rowspan="1">[<xref rid="bb0715" ref-type="bibr">143</xref>]</td></tr><tr><td colspan="1" rowspan="1">Imperial College, London<break/>Acuitas Therapeutics, Vancouver</td><td colspan="1" rowspan="1">LNP-nCoV saRNA<break/><break/>ARCT-021</td><td colspan="1" rowspan="1">saRNA and pre-fusion stabilized SARS-CoV-2 S protein</td><td colspan="1" rowspan="1">LNP with saRNA encapsulated</td><td colspan="1" rowspan="1">ISRCTN1707269, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04480957">NCT04480957</ext-link></td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Suzhou Abogen Biosciences<break/>Walvax Biotechnology and People's Liberation Army</td><td colspan="1" rowspan="1">ARCoV</td><td colspan="1" rowspan="1">mRNA encoding RBD of SARS-CoV-2 S glycoprotein</td><td colspan="1" rowspan="1">LNP with mRNA encapsulated</td><td colspan="1" rowspan="1">Phase I (ChiCTR2000034112)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">SARS-CoV S protein and influenza M1 protein</td><td colspan="1" rowspan="1">SARS-CoV VLP nanovaccine</td><td colspan="1" rowspan="1">Preclinical</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Imophoron and Bristol University</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Multiepitope display</td><td colspan="1" rowspan="1">VLP ADDomer&#8482;</td><td colspan="1" rowspan="1">Preclinical</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/news/2020/april/covid-19-vaccine-platform.html" id="ir0005">http://www.bristol.ac.uk/news/2020/april/covid-19-vaccine-platform.html</ext-link></td></tr><tr><td colspan="1" rowspan="1">Fundan University, Shanghai JiaoTong University, and RNACure Biopharma</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">mRNA cocktail</td><td colspan="1" rowspan="1">LNP with VLP encapsulated</td><td colspan="1" rowspan="1">Preclinical</td><td colspan="1" rowspan="1">[<xref rid="bb0720" ref-type="bibr">144</xref>]</td></tr><tr><td colspan="1" rowspan="1">Crucell</td><td colspan="1" rowspan="1">Inflexal&#174;V</td><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Virosome with influenza virus surface antigens (hemagglutinin and neuraminidase)</td><td colspan="1" rowspan="1">Phase III completed<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01631110">NCT01631110</ext-link></td><td colspan="1" rowspan="1">EMA</td></tr><tr><td colspan="1" rowspan="1">Crucell</td><td colspan="1" rowspan="1">Epaxal&#174;</td><td colspan="1" rowspan="1">Hepatitis A</td><td colspan="1" rowspan="1">Virosome with inactivated virus particles</td><td colspan="1" rowspan="1">Phase III completed<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01307436">NCT01307436</ext-link></td><td colspan="1" rowspan="1">EMA</td></tr><tr><td colspan="1" rowspan="1">Merck</td><td colspan="1" rowspan="1">Gardasil&#174;9</td><td colspan="1" rowspan="1">HPV</td><td colspan="1" rowspan="1">Capsomere (major capsid protein L1)</td><td colspan="1" rowspan="1">Completed<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00090220">NCT00090220</ext-link></td><td colspan="1" rowspan="1">FDA<break/>EMA</td></tr><tr><td colspan="1" rowspan="1">GSK</td><td colspan="1" rowspan="1">Cervarix&#174;</td><td colspan="1" rowspan="1">HPV</td><td colspan="1" rowspan="1">Capsomere (major capsid protein L1)</td><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00316693">NCT00316693</ext-link><break/>Phase III<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03728881">NCT03728881</ext-link></td><td colspan="1" rowspan="1">FDA<break/>EMA</td></tr><tr><td colspan="1" rowspan="1">Dendreon Pharmaceuticals</td><td colspan="1" rowspan="1">Provenge (Sipuleucel-T)</td><td colspan="1" rowspan="1">Prostate cancer</td><td colspan="1" rowspan="1">Each dose of contains a minimum of 50 million autologous CD54<sup>+</sup> cells activated with PAP-GM-CSF</td><td colspan="1" rowspan="1">Phase III completed<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00065442">NCT00065442</ext-link></td><td colspan="1" rowspan="1">FDA</td></tr><tr><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">NanoFlu<sup>TM</sup></td><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">Recombinant HA protein on Tween 80 NP with Matrix-M adjuvant</td><td colspan="1" rowspan="1">Phase III<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04120194">NCT04120194</ext-link></td><td colspan="1" rowspan="1">Active</td></tr><tr><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">ResVax<sup>TM</sup></td><td colspan="1" rowspan="1">RSV (protection of infants via maternal immunization)</td><td colspan="1" rowspan="1">Recombinant near full-length RSV F protein on Tween 80 NP with/without alum adjuvant</td><td colspan="1" rowspan="1">Phase III<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02624947">NCT02624947</ext-link><break/>2016-002302-39</td><td colspan="1" rowspan="1">Completed (2020)</td></tr><tr><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">ResVax<sup>TM</sup> (coadministration with influenza vaccine)</td><td colspan="1" rowspan="1">RSV and influenza (&#8805;60 years of age)</td><td colspan="1" rowspan="1">Recombinant near full-length RSV F protein on Tween 80 NP with/without alum adjuvant coadministered with licensed influenza vaccine</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01709019">NCT01709019</ext-link></td><td colspan="1" rowspan="1">Completed (2014)</td></tr><tr><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">EBOV GP Vaccine</td><td colspan="1" rowspan="1">Ebola</td><td colspan="1" rowspan="1">2014 Guinea Ebola virus recombinant glycoprotein on Tween 80 NP with/without Matrix-M adjuvant</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02370589">NCT02370589</ext-link></td><td colspan="1" rowspan="1">Completed (2016)</td></tr><tr><td colspan="1" rowspan="1">Sensei Biotherapeutics</td><td colspan="1" rowspan="1">PAN-301-1</td><td colspan="1" rowspan="1">Prostate cancer</td><td colspan="1" rowspan="1">Modified bacteriophage (viral NP) expressing 200&#8211;300 copies of part of the human aspartyl (asparaginyl) &#946;-hydroxylase molecule on the viral head</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03120832">NCT03120832</ext-link></td><td colspan="1" rowspan="1">Completed (2019)</td></tr><tr><td colspan="1" rowspan="1">DAIDS/NIAID/NIH</td><td colspan="1" rowspan="1">MPER-656</td><td colspan="1" rowspan="1">HIV</td><td colspan="1" rowspan="1">HIV-1 gp41 membrane proximal external region (MPER) with liposomes</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03934541">NCT03934541</ext-link></td><td colspan="1" rowspan="1">Active</td></tr><tr><td colspan="1" rowspan="1">BioNTech</td><td colspan="1" rowspan="1">W_ova1</td><td colspan="1" rowspan="1">Ovarian cancer</td><td colspan="1" rowspan="1">Liposome-formulated mRNAs. Three ovarian cancer tumor-associated antigens in combination with (neo-)adjuvant chemotherapy</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04163094">NCT04163094</ext-link></td><td colspan="1" rowspan="1">Active</td></tr><tr><td colspan="1" rowspan="1">ImmunoVaccine Technologies</td><td colspan="1" rowspan="1">DPX-0907</td><td colspan="1" rowspan="1">Ovarian, breast, and prostate cancer</td><td colspan="1" rowspan="1">Liposomes with seven tumor-specific HLA-A2-restricted peptides, a universal T helper peptide, and a polynucleotide adjuvant in Montanide ISA51 VG</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01095848">NCT01095848</ext-link></td><td colspan="1" rowspan="1">Completed (2015)</td></tr><tr><td rowspan="7" colspan="1">Merck</td><td rowspan="7" colspan="1">Tecemotide</td><td colspan="1" rowspan="1">Multiple myeloma</td><td colspan="1" rowspan="1">Liposomes with tecemotide lipopeptide and 3-<italic toggle="yes">O</italic>-deacyl-4&#8242;-monophosphoryl lipid adjuvant</td><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01094548">NCT01094548</ext-link></td><td colspan="1" rowspan="1">Completed (2016)</td></tr><tr><td colspan="1" rowspan="1">NSCLC (discontinued)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Phase I/II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00960115">NCT00960115</ext-link><break/>Phase III<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01015443">NCT01015443</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02049151">NCT02049151</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00409188">NCT00409188</ext-link></td><td colspan="1" rowspan="1">Completed (2015)<break/>Terminated for NSCLC indication</td></tr><tr><td colspan="1" rowspan="1">NSCLC<break/>(bevacizumab)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00828009">NCT00828009</ext-link></td><td colspan="1" rowspan="1">Active</td></tr><tr><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Phase III<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00925548">NCT00925548</ext-link></td><td colspan="1" rowspan="1">Terminated (clinical hold)</td></tr><tr><td colspan="1" rowspan="1">Colon/rectum carcinoma</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01462513">NCT01462513</ext-link></td><td colspan="1" rowspan="1">Completed (2018)</td></tr><tr><td colspan="1" rowspan="1">Prostate cancer</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01496131">NCT01496131</ext-link></td><td colspan="1" rowspan="1">Completed (2018)</td></tr><tr><td colspan="1" rowspan="1">Rectal cancer</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01507103">NCT01507103</ext-link></td><td colspan="1" rowspan="1">Completed (2017)</td></tr><tr><td colspan="1" rowspan="1">Cascadian Therapeutics</td><td colspan="1" rowspan="1">ONT-10</td><td colspan="1" rowspan="1">Solid tumor</td><td colspan="1" rowspan="1">Liposomal MUC1 cancer vaccine</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01556789">NCT01556789</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01978964">NCT01978964</ext-link></td><td colspan="1" rowspan="1">Completed<break/>(2018)<break/>(2018)</td></tr><tr><td colspan="1" rowspan="1">XEME Biopharma</td><td colspan="1" rowspan="1">Oncoquest<sup>TM</sup></td><td colspan="1" rowspan="1">Follicular lymphoma<break/>Chronic lymphocytic leukemia</td><td colspan="1" rowspan="1">Liposomes containing autologous tumor-derived antigen and IL-2</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01976520">NCT01976520</ext-link><break/>Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02194751">NCT02194751</ext-link></td><td colspan="1" rowspan="1">Active<break/><break/>Active</td></tr><tr><td colspan="1" rowspan="1">Lipotek Pty</td><td colspan="1" rowspan="1">Lipovaxin-MM</td><td colspan="1" rowspan="1">Metastatic melanoma</td><td colspan="1" rowspan="1">Multicomponent liposomes containing tumor antigens (gp100, tyrosinase, and melanA/MART-1) with DC-targeting moiety DMS-5000</td><td colspan="1" rowspan="1">Phase I<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01052142">NCT01052142</ext-link></td><td colspan="1" rowspan="1">Completed (2012)</td></tr><tr><td colspan="1" rowspan="1">NasVax</td><td colspan="1" rowspan="1">VaxiSome<sup>TM</sup>-Influenza</td><td colspan="1" rowspan="1">Influenza</td><td colspan="1" rowspan="1">VaxiSome<sup>TM</sup> (ceramide carbamoyl-spermine/cholesterol) liposomal adjuvant/delivery system combined with commercial influenza vaccine</td><td colspan="1" rowspan="1">Phase II<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00915187">NCT00915187</ext-link></td><td colspan="1" rowspan="1">Completed (2011)</td></tr></tbody></table><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">Abbreviations: ARE, <italic toggle="yes">Asparagus racemosus</italic> extract; CsAuNPs, chitosan-functionalized AuNPs; F, RSV fusion protein; HA, influenza virus hemagglutinin; HPV, human papillomavirus; LNP, lipid nanoparticle; melanA/MART-1, melanoma antigen recognized by T cells; MUC1, mucin 1; NSCLC, non-small cell lung cancer; PAP-GM-CSF, pulmonary alveolar proteinosis granulocyte macrophage colony-stimulating factor; RBD, receptor-binding domain; RSV, respiratory syncytial virus; S, SARS-CoV-19 spike protein; saRNA, self-amplifying mRNA; VLP, vaccine-like particle.</p></fn></table-wrap-foot></table-wrap></p><p id="p0185">Boston-based Moderna in conjunction with the National Institute of Allergy and Infectious Diseases (NIAID) developed a mRNA-based NP vaccine against SARS-CoV-2 [<xref rid="bb0695" ref-type="bibr">139</xref>]. The mRNA contains the coding sequence for SARS-CoV-2 spike (S) protein and is encapsulated within lipid NPs that induce efficient uptake by immune cells and the activation of T and B lymphocytes [<xref rid="bb0695" ref-type="bibr">139</xref>]. An adaptive immune response is thus generated against the S protein [<xref rid="bb0695" ref-type="bibr">139</xref>,<xref rid="bb0700" ref-type="bibr">140</xref>]. Pfizer and BioNTech jointly developed the BNT162 (b1, b2) vaccine against SARS-CoV-2. BNT162b1 is mRNA-based vaccine that encodes a trimer of the viral receptor-binding domain (RBD) [<xref rid="bb0705" ref-type="bibr">141</xref>]. BNT162b2 is another mRNA vaccine which codes for full-length membrane-anchored S protein [<xref rid="bb0710" ref-type="bibr">142</xref>]. Both mRNAs are encapsulated in lipid NPs for efficient delivery into target cells. The mRNA sequences are partially modified to enhance RNA stability and protect the RNA conformation to improve immunogenicity [<xref rid="bb0705" ref-type="bibr">141</xref>,<xref rid="bb0710" ref-type="bibr">142</xref>]. The Moderna and BNT vaccines were the among the first approved vaccines against SARS-CoV-2. Maryland-based Novavax expressed full-length SARS-CoV-2 S glycoprotein in a baculovirus/Sf9 system. The saponin-based Matrix-M1 adjuvant is used during administration, which overcomes the problem of not inducing a cell-mediated immune response observed with other protein subunit vaccines [<xref rid="bb0715" ref-type="bibr">143</xref>]. The Novavax vaccine is currently under review for emergency use authorization (EUA).</p><p id="p0190">In addition to SARS-CoV-2, the use of nanovaccines is widespread in multiple other diseases as well. Many of them have been approved by FDA and/or European Medicines Agency (EMA) and others are currently in clinical trials. A list of such vaccines is provided in <xref rid="t0010" ref-type="table">Table 2</xref>.</p></sec><sec id="s0045"><title>Concluding remarks and future perspectives</title><p id="p0195">Despite advances in the development of traditional vaccines, improvements are needed because of the weak immunogenicity of conventional vaccines, intrinsic instability <italic toggle="yes">in vivo</italic>, toxicity, and the need for multiple booster immunizations. Nanovaccines, which are the focus of this review, provide distinct advantages over conventional vaccines because of their size proximity to pathogens, controllable physicochemical and biophysical attributes, enhanced protection of the antigen from degradation, biopersistence, improved transport through the lymphatics and into LNs, and codelivery of immunomodulatory molecules to boost immune recognition (<xref rid="b0005" ref-type="boxed-text">Box 1</xref>, <xref rid="b0010" ref-type="boxed-text">Box 2</xref>).<boxed-text id="b0010" position="float" orientation="portrait"><label>Box 2</label><caption><title>The future of nanovaccines</title></caption><p id="p0040">Personalized nanovaccines</p><p id="p0045">Different immunization efficiencies have been reported in different groups (young/adults, diabetic/non-diabetic, male/female, etc.) during the development of different coronavirus disease 2019 (COVID-19) vaccines. Nanotools can offer a range of advanced strategies to potentially develop a seasonal vaccine where one infection may possibly facilitate other infections (e.g., influenza infection can facilitate bacterial superinfection and pneumonia; coinfection with influenza A virus can enhance SARS-CoV-2 infectivity). It remains to be determined whether nanovaccines with multiple epitopes and/or adjuvants can be developed to generate broad-spectrum immunity. Nanotools offer the best possible non-viral strategy to encapsulate and deliver nucleic acids (including plasmids and mRNA), although thermostability remains an unresolved issue. It is well established that the immune system is differently configured in different individuals, and a 'one-size-fits-all' approach is not an optimal solution &#8211; nanovaccines hold potential in the development of a new frontier of personalized vaccines that will ensure wider and longer-term protection (<xref rid="f0025" ref-type="fig">Figure I</xref>).<fig id="f0025" position="float" orientation="portrait"><label>Figure I</label><caption><p>Future nanovaccines.</p></caption><alt-text id="al0045">Figure I</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="b1.jpg"/></fig></p><notes notes-type="alt-text" specific-use="for-accessibility" id="al0040"><p>Alt-text: Box 2</p></notes></boxed-text></p><p id="p0200">Recent advances in nanoengineering have played a pivotal role in developing the highly anticipated liposome-based mRNA vaccine against SARS-CoV-2. Nevertheless, there are unanswered challenges in the path of successful translation of various nanovaccines. The nanoscale size range of the antigen vehicle is a crucial criterion which determines the spatial location of the antigen. The optimum size is not generalizable and depends on several factors such as the chemical composition of the nanovaccine and opsonization by complement and complement receptors. Understanding how nanovaccines elicit clonal bursts and somatic hypermutation needs to be addressed for the design of improved nanovaccines against highly variable viruses such as SARS-CoV-2 and influenza, where the success of immunization depends on eliciting extensive somatic hypermutation in antibody-secreting B cells.</p><p id="p0205">Finally, the promise of nanovaccines does not end with the simple induction of humoral or cell-mediated immunity, and nanovaccines represent a new frontier in the development personalized vaccines (<xref rid="b0010" ref-type="boxed-text">Box 2</xref>). However, many issues remain unresolved (see <xref rid="b0015" ref-type="boxed-text">Outstanding questions</xref>) and a risk&#8211;benefit analysis is required. Once preclinical studies are validated in animal models, clinical translation of nanovaccines will require stringent safety testing to address different types of risks and scenarios (<xref rid="b0010" ref-type="boxed-text">Box 2</xref>). In addition, setting up an analytical pipeline for the development of nanovaccines of different compositions will require further systematic investigations.<boxed-text id="b0015" position="float" orientation="portrait"><label>Outstanding questions</label><p id="p0210">Can nanoscale materials be used to facilitate vaccine development?</p><p id="p0215">How do nanoscale properties such as size, shape, geometry, and surface functionalization contribute toward an effective immune response?</p><p id="p0220">How do nanovaccines complement the vaccine development process in the current pandemic scenario?</p><p id="p0225">Is it possible to acquire and track indicators of the long-term impact of nanovaccines over the lifetime of an individual?</p><notes notes-type="alt-text" specific-use="for-accessibility" id="al0050"><p>Alt-text: Outstanding questions</p></notes></boxed-text></p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1.</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name name-style="western"><surname>Arias</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>B.E.</given-names></name></person-group><article-title>Antibiotic-resistant bugs in the 21st century &#8211; a clinical super-challenge</article-title><source>N. Engl. J. Med.</source><volume>360</volume><year>2009</year><fpage>439</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">19179312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp0804651</pub-id></element-citation></ref><ref id="bb0010"><label>2.</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Human autoimmune diseases: a comprehensive update</article-title><source>J. Intern. Med.</source><volume>278</volume><year>2015</year><fpage>369</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">26212387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.12395</pub-id></element-citation></ref><ref id="bb0015"><label>3.</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name name-style="western"><surname>Rosenblum</surname><given-names>M.D.</given-names></name><etal/></person-group><article-title>Mechanisms of human autoimmunity</article-title><source>J. Clin. Invest.</source><volume>125</volume><year>2015</year><fpage>2228</fpage><lpage>2233</lpage><pub-id pub-id-type="pmid">25893595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI78088</pub-id><pub-id pub-id-type="pmcid">PMC4518692</pub-id></element-citation></ref><ref id="bb0020"><label>4.</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name name-style="western"><surname>Koff</surname><given-names>W.C.</given-names></name></person-group><article-title>A shot at AIDS</article-title><source>Curr. Opin. Biotechnol.</source><volume>42</volume><year>2016</year><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">27153215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.copbio.2016.03.007</pub-id></element-citation></ref><ref id="bb0025"><label>5.</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>B.</given-names></name></person-group><article-title>The contribution of vaccination to global health: past, present and future</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><volume>369</volume><year>2014</year><object-id pub-id-type="publisher-id">20130433</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmcid">PMC4024226</pub-id><pub-id pub-id-type="pmid">24821919</pub-id></element-citation></ref><ref id="bb0030"><label>6.</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name name-style="western"><surname>Al-Halifa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Nanoparticle-based vaccines against respiratory viruses</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>22</fpage><pub-id pub-id-type="pmid">30733717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00022</pub-id><pub-id pub-id-type="pmcid">PMC6353795</pub-id></element-citation></ref><ref id="bb0035"><label>7.</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name name-style="western"><surname>Kheirollahpour</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Nanoparticles and vaccine development</article-title><source>Pharm. Nanotechnol.</source><volume>8</volume><year>2020</year><fpage>6</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">31647394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/2211738507666191024162042</pub-id></element-citation></ref><ref id="bb0040"><label>8.</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Applications of nanotechnology for immunology</article-title><source>Nat. Rev. Immunol.</source><volume>13</volume><year>2013</year><fpage>592</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">23883969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3488</pub-id><pub-id pub-id-type="pmcid">PMC7097370</pub-id></element-citation></ref><ref id="bb0045"><label>9.</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Synthetic nanoparticles for vaccines and immunotherapy</article-title><source>Chem. Rev.</source><volume>115</volume><year>2015</year><fpage>11109</fpage><lpage>11146</lpage><pub-id pub-id-type="pmid">26154342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.5b00109</pub-id><pub-id pub-id-type="pmcid">PMC4688911</pub-id></element-citation></ref><ref id="bb0050"><label>10.</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles</article-title><source>J. Control. Release</source><volume>219</volume><year>2015</year><fpage>488</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">26433125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2015.09.046</pub-id><pub-id pub-id-type="pmcid">PMC4745091</pub-id></element-citation></ref><ref id="bb0055"><label>11.</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a <italic toggle="yes">Plasmodium vivax</italic> malaria vaccine</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e31472</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0031472</pub-id><pub-id pub-id-type="pmcid">PMC3273465</pub-id><pub-id pub-id-type="pmid">22328935</pub-id></element-citation></ref><ref id="bb0060"><label>12.</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The antimicrobial activity of nanoparticles &#8211; present situation</article-title><source>Int. J. Nanomedicine</source><volume>12</volume><year>2017</year><fpage>1227</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">28243086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S121956</pub-id><pub-id pub-id-type="pmcid">PMC5317269</pub-id></element-citation></ref><ref id="bb0065"><label>13.</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R.S.</given-names></name></person-group><article-title>Immunological evaluation of colonic delivered hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles</article-title><source>Int. Immunopharmacol.</source><volume>39</volume><year>2016</year><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">27526270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2016.08.007</pub-id></element-citation></ref><ref id="bb0070"><label>14.</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C.M.J.</given-names></name><etal/></person-group><article-title>Nanoparticle-detained toxins for safe and effective vaccination</article-title><source>Nat. Nanotechnol.</source><volume>8</volume><year>2013</year><fpage>933</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">24292514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2013.254</pub-id><pub-id pub-id-type="pmcid">PMC3878426</pub-id></element-citation></ref><ref id="bb0075"><label>15.</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name name-style="western"><surname>Farris</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Micro- and nanoparticulates for DNA vaccine delivery</article-title><source>Exp. Biol. Med.</source><volume>241</volume><year>2016</year><fpage>919</fpage><lpage>929</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1535370216643771</pub-id><pub-id pub-id-type="pmcid">PMC4950349</pub-id><pub-id pub-id-type="pmid">27048557</pub-id></element-citation></ref><ref id="bb0080"><label>16.</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Nanoparticle-based antivirulence vaccine for the management of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> skin infection</article-title><source>Adv. Funct. Mater.</source><volume>26</volume><year>2016</year><fpage>1628</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">27325913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adfm.201505231</pub-id><pub-id pub-id-type="pmcid">PMC4912041</pub-id></element-citation></ref><ref id="bb0085"><label>17.</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>CpG ODN as an adjuvant arouses the vigor of B cells by relieving the negative regulation of surface TLR9 to enhance the antibody response to vaccine</article-title><source>Appl. Microbiol. Biotechnol.</source><volume>105</volume><year>2021</year><fpage>4213</fpage><lpage>4224</lpage><pub-id pub-id-type="pmid">33950279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00253-021-11316-9</pub-id></element-citation></ref><ref id="bb0090"><label>18.</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>V.B.</given-names></name><etal/></person-group><article-title>Biodegradable particles as vaccine delivery systems: size matters</article-title><source>AAPS J.</source><volume>15</volume><year>2013</year><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">23054976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-012-9418-6</pub-id><pub-id pub-id-type="pmcid">PMC3535111</pub-id></element-citation></ref><ref id="bb0095"><label>19.</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamachari</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Nanoparticle delivery systems in cancer vaccines</article-title><source>Pharm. Res.</source><volume>28</volume><year>2011</year><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">20721603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-010-0241-4</pub-id><pub-id pub-id-type="pmcid">PMC3559243</pub-id></element-citation></ref><ref id="bb0100"><label>20.</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Synthetic nanovaccines for immunotherapy</article-title><source>J. Control. Release</source><volume>263</volume><year>2017</year><fpage>200</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">28336379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.03.033</pub-id><pub-id pub-id-type="pmcid">PMC5603379</pub-id></element-citation></ref><ref id="bb0105"><label>21.</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name name-style="western"><surname>Azharuddin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A repertoire of biomedical applications of noble metal nanoparticles</article-title><source>Chem. Commun.</source><volume>55</volume><year>2019</year><fpage>6964</fpage><lpage>6996</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9cc01741k</pub-id><pub-id pub-id-type="pmid">31140997</pub-id></element-citation></ref><ref id="bb0110"><label>22.</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Gold nanoparticle&#8211;M2e conjugate coformulated with CpG induces protective immunity against influenza A virus</article-title><source>Nanomedicine</source><volume>9</volume><year>2014</year><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">23829488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/nnm.13.58</pub-id><pub-id pub-id-type="pmcid">PMC3958969</pub-id></element-citation></ref><ref id="bb0115"><label>23.</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Nanovaccines for malaria using <italic toggle="yes">Plasmodium falciparum</italic> antigen Pfs25 attached gold nanoparticles</article-title><source>Vaccine</source><volume>33</volume><year>2015</year><fpage>5064</fpage><lpage>5071</lpage><pub-id pub-id-type="pmid">26299750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.08.025</pub-id><pub-id pub-id-type="pmcid">PMC4577455</pub-id></element-citation></ref><ref id="bb0120"><label>24.</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy</article-title><source>Adv. Healthc. Mater.</source><volume>3</volume><year>2014</year><fpage>1194</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">24652754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201300597</pub-id></element-citation></ref><ref id="bb0125"><label>25.</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name name-style="western"><surname>Falagan-Lotsch</surname><given-names>P.</given-names></name><etal/></person-group><article-title>One low-dose exposure of gold nanoparticles induces long-term changes in human cells</article-title><source>Proc. Natl. Acad. Sci.</source><volume>113</volume><year>2016</year><fpage>13318</fpage><lpage>13323</lpage><pub-id pub-id-type="pmid">27821760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1616400113</pub-id><pub-id pub-id-type="pmcid">PMC5127334</pub-id></element-citation></ref><ref id="bb0130"><label>26.</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>H.A.F.M.</given-names></name><etal/></person-group><article-title>Application of carbon nanotubes in cancer vaccines: achievements, challenges and chances</article-title><source>J. Control. Release</source><volume>297</volume><year>2019</year><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">30659906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2019.01.017</pub-id></element-citation></ref><ref id="bb0135"><label>27.</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name name-style="western"><surname>Tyner</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro</article-title><source>Int. J. Nanomedicine</source><year>2014</year><fpage>183</fpage><lpage>206</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S72580</pub-id><pub-id pub-id-type="pmcid">PMC4284048</pub-id><pub-id pub-id-type="pmid">25565813</pub-id></element-citation></ref><ref id="bb0140"><label>28.</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma</article-title><source>ACS Nano</source><volume>9</volume><year>2015</year><fpage>6918</fpage><lpage>6933</lpage><pub-id pub-id-type="pmid">26153897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.5b01042</pub-id></element-citation></ref><ref id="bb0145"><label>29.</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name name-style="western"><surname>Tafaghodi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved <italic toggle="yes">Leishmania major</italic> (ALM) and CpG-ODN</article-title><source>Parasitol. Res.</source><volume>108</volume><year>2011</year><fpage>1265</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">21125294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00436-010-2176-4</pub-id></element-citation></ref><ref id="bb0150"><label>30.</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name name-style="western"><surname>Athanasiou</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A poly(lactic-co-glycolic) acid nanovaccine based on chimeric peptides from different <italic toggle="yes">Leishmania infantum</italic> proteins induces dendritic cells maturation and promotes peptide-specific IFN&#947;-producing CD8<sup>+</sup> T cells essential for the protection against experimental visceral leishmaniasis</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>684</fpage><pub-id pub-id-type="pmid">28659922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00684</pub-id><pub-id pub-id-type="pmcid">PMC5468442</pub-id></element-citation></ref><ref id="bb0155"><label>31.</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name name-style="western"><surname>Vicente</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A polymer/oil based nanovaccine as a single-dose immunization approach</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e62500</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0062500</pub-id><pub-id pub-id-type="pmcid">PMC3632546</pub-id><pub-id pub-id-type="pmid">23614052</pub-id></element-citation></ref><ref id="bb0160"><label>32.</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name name-style="western"><surname>Vela Ramirez</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells</article-title><source>J. Biomater. Sci. Polym. Ed.</source><volume>25</volume><year>2014</year><fpage>1387</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">25068589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09205063.2014.940243</pub-id><pub-id pub-id-type="pmcid">PMC4465578</pub-id></element-citation></ref><ref id="bb0165"><label>33.</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name name-style="western"><surname>Kakwere</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Toward personalized peptide-based cancer nanovaccines: a facile and versatile synthetic approach</article-title><source>Bioconjug. Chem.</source><volume>28</volume><year>2017</year><fpage>2756</fpage><lpage>2771</lpage><pub-id pub-id-type="pmid">28956907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.7b00502</pub-id><pub-id pub-id-type="pmcid">PMC5687982</pub-id></element-citation></ref><ref id="bb0170"><label>34.</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Self-adjuvanted nanovaccine for cancer immunotherapy: role of lysosomal rupture-induced ROS in MHC class I antigen presentation</article-title><source>Biomaterials</source><volume>79</volume><year>2016</year><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">26702587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2015.11.040</pub-id></element-citation></ref><ref id="bb0175"><label>35.</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy</article-title><source>J. Control. Release</source><volume>170</volume><year>2013</year><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">23742880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2013.05.027</pub-id></element-citation></ref><ref id="bb0180"><label>36.</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine</article-title><source>Cell Discov.</source><volume>3</volume><year>2017</year><fpage>17007</fpage><pub-id pub-id-type="pmid">28417012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/celldisc.2017.7</pub-id><pub-id pub-id-type="pmcid">PMC5379745</pub-id></element-citation></ref><ref id="bb0185"><label>37.</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo</article-title><source>Biomaterials</source><volume>38</volume><year>2015</year><fpage>50</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">25457983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2014.10.050</pub-id></element-citation></ref><ref id="bb0190"><label>38.</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response</article-title><source>Biomaterials</source><volume>149</volume><year>2017</year><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">28992509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2017.09.029</pub-id></element-citation></ref><ref id="bb0195"><label>39.</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name name-style="western"><surname>Dhakal</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs</article-title><source>Int. J. Nanomedicine</source><volume>13</volume><year>2018</year><fpage>6699</fpage><lpage>6715</lpage><pub-id pub-id-type="pmid">30425484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S178809</pub-id><pub-id pub-id-type="pmcid">PMC6205527</pub-id></element-citation></ref><ref id="bb0200"><label>40.</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system</article-title><source>Angew. Chemie. Int. Ed.</source><volume>49</volume><year>2010</year><fpage>5742</fpage><lpage>5745</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201002221</pub-id><pub-id pub-id-type="pmid">20818757</pub-id></element-citation></ref><ref id="bb0205"><label>41.</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy</article-title><source>Biomaterials</source><volume>207</volume><year>2019</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30947117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.03.037</pub-id></element-citation></ref><ref id="bb0210"><label>42.</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name name-style="western"><surname>El Bissati</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Protein nanovaccine confers robust immunity against <italic toggle="yes">Toxoplasma</italic></article-title><source>NPJ Vaccines</source><volume>2</volume><year>2017</year><fpage>24</fpage><pub-id pub-id-type="pmid">29263879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-017-0024-6</pub-id><pub-id pub-id-type="pmcid">PMC5627305</pub-id></element-citation></ref><ref id="bb0215"><label>43.</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>In vivo assembly of nanoparticles achieved through synergy of structure-based protein engineering and synthetic DNA generates enhanced adaptive immunity</article-title><source>Adv. Sci.</source><volume>7</volume><year>2020</year><object-id pub-id-type="publisher-id">1902802</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.201902802</pub-id><pub-id pub-id-type="pmcid">PMC7175333</pub-id><pub-id pub-id-type="pmid">32328416</pub-id></element-citation></ref><ref id="bb0220"><label>44.</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name name-style="western"><surname>Gause</surname><given-names>K.T.</given-names></name><etal/></person-group><article-title>Immunological principles guiding the rational design of particles for vaccine delivery</article-title><source>ACS Nano</source><volume>11</volume><year>2017</year><fpage>54</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">28075558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.6b07343</pub-id></element-citation></ref><ref id="bb0225"><label>45.</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name name-style="western"><surname>Naahidi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Biocompatibility of engineered nanoparticles for drug delivery</article-title><source>J. Control. Release</source><volume>166</volume><year>2013</year><fpage>182</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">23262199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2012.12.013</pub-id></element-citation></ref><ref id="bb0230"><label>46.</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name name-style="western"><surname>Niikura</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo</article-title><source>ACS Nano</source><volume>7</volume><year>2013</year><fpage>3926</fpage><lpage>3938</lpage><pub-id pub-id-type="pmid">23631767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn3057005</pub-id></element-citation></ref><ref id="bb0235"><label>47.</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Del Rio</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax<sup>TM</sup> delta inulin adjuvant induces robust T-cell protection against listeria infection</article-title><source>Vaccine</source><volume>33</volume><year>2015</year><fpage>1465</fpage><lpage>1473</lpage><pub-id pub-id-type="pmid">25659269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.01.062</pub-id></element-citation></ref><ref id="bb0240"><label>48.</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide</article-title><source>Nanotechnology</source><volume>21</volume><year>2010</year><object-id pub-id-type="publisher-id">195101</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/0957-4484/21/19/195101</pub-id><pub-id pub-id-type="pmid">20400818</pub-id></element-citation></ref><ref id="bb0245"><label>49.</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name name-style="western"><surname>Barhate</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment</article-title><source>J. Pharm. Sci.</source><volume>103</volume><year>2014</year><fpage>3448</fpage><lpage>3456</lpage><pub-id pub-id-type="pmid">25219511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.24161</pub-id></element-citation></ref><ref id="bb0250"><label>50.</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name name-style="western"><surname>McCoy</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Mechanisms of protective immune responses induced by the <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein-based, self-assembling protein nanoparticle vaccine</article-title><source>Malar. J.</source><volume>12</volume><year>2013</year><fpage>136</fpage><pub-id pub-id-type="pmid">23607541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-12-136</pub-id><pub-id pub-id-type="pmcid">PMC3765086</pub-id></element-citation></ref><ref id="bb0255"><label>51.</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name name-style="western"><surname>Kaba</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Protective antibody and CD8<sup>+</sup> T-cell responses to the <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein induced by a nanoparticle vaccine</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e48304</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0048304</pub-id><pub-id pub-id-type="pmcid">PMC3483151</pub-id><pub-id pub-id-type="pmid">23144750</pub-id></element-citation></ref><ref id="bb0260"><label>52.</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name name-style="western"><surname>Staroverov</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Immunostimulatory effect of gold nanoparticles conjugated with transmissible gastroenteritis virus</article-title><source>Bull. Exp. Biol. Med.</source><volume>151</volume><year>2011</year><fpage>436</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">22448360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10517-011-1350-8</pub-id><pub-id pub-id-type="pmcid">PMC7087599</pub-id></element-citation></ref><ref id="bb0265"><label>53.</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name name-style="western"><surname>Parween</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Induction of humoral immune response against PfMSP-119 and PvMSP-119 using gold nanoparticles along with alum</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>2451</fpage><lpage>2460</lpage><pub-id pub-id-type="pmid">21288801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.01.014</pub-id></element-citation></ref><ref id="bb0270"><label>54.</label><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name name-style="western"><surname>Kaba</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria</article-title><source>J. Immunol.</source><volume>183</volume><year>2009</year><fpage>7268</fpage><lpage>7277</lpage><pub-id pub-id-type="pmid">19915055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0901957</pub-id><pub-id pub-id-type="pmcid">PMC4528972</pub-id></element-citation></ref><ref id="bb0275"><label>55.</label><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine</article-title><source>Vaccine</source><volume>33</volume><year>2015</year><fpage>686</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">25533326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.11.057</pub-id><pub-id pub-id-type="pmcid">PMC4304905</pub-id></element-citation></ref><ref id="bb0280"><label>56.</label><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>A gold nanoparticle-linked glycoconjugate vaccine against <italic toggle="yes">Burkholderia mallei</italic></article-title><source>Nanomedicine Nanotechnol. Biol. Med.</source><volume>11</volume><year>2015</year><fpage>447</fpage><lpage>456</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2014.08.005</pub-id><pub-id pub-id-type="pmcid">PMC4330121</pub-id><pub-id pub-id-type="pmid">25194998</pub-id></element-citation></ref><ref id="bb0285"><label>57.</label><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name name-style="western"><surname>Demento</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines</article-title><source>Trends Biotechnol.</source><volume>29</volume><year>2011</year><fpage>294</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">21459467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2011.02.004</pub-id><pub-id pub-id-type="pmcid">PMC7025712</pub-id></element-citation></ref><ref id="bb0290"><label>58.</label><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name name-style="western"><surname>Sahdev</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Biomaterials for nanoparticle vaccine delivery systems</article-title><source>Pharm. Res.</source><volume>31</volume><year>2014</year><fpage>2563</fpage><lpage>2582</lpage><pub-id pub-id-type="pmid">24848341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-014-1419-y</pub-id><pub-id pub-id-type="pmcid">PMC4198431</pub-id></element-citation></ref><ref id="bb0295"><label>59.</label><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>G.T.</given-names></name></person-group><article-title>Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns</article-title><source>Nat. Rev. Immunol.</source><volume>10</volume><year>2010</year><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">20948547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2868</pub-id></element-citation></ref><ref id="bb0300"><label>60.</label><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name name-style="western"><surname>Oyewumi</surname><given-names>M.O.</given-names></name><etal/></person-group><article-title>Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses</article-title><source>Expert Rev. Vaccines</source><volume>9</volume><year>2010</year><fpage>1095</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">20822351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.10.89</pub-id><pub-id pub-id-type="pmcid">PMC2963573</pub-id></element-citation></ref><ref id="bb0305"><label>61.</label><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name name-style="western"><surname>Petros</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Desimone</surname><given-names>J.M.</given-names></name></person-group><article-title>Strategies in the design of nanoparticles for therapeutic applications</article-title><source>Nat. Rev. Drug Discov.</source><volume>9</volume><year>2010</year><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">20616808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2591</pub-id></element-citation></ref><ref id="bb0310"><label>62.</label><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Norkin</surname><given-names>L.C.</given-names></name></person-group><article-title>Extracellular simian virus 40 transmits a signal that promotes virus enclosure within caveolae</article-title><source>Exp. Cell Res.</source><volume>246</volume><year>1999</year><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9882517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/excr.1998.4301</pub-id></element-citation></ref><ref id="bb0315"><label>63.</label><element-citation publication-type="journal" id="rf0315"><person-group person-group-type="author"><name name-style="western"><surname>Daecke</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>1581</fpage><lpage>1594</lpage><pub-id pub-id-type="pmid">15650184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.79.3.1581-1594.2005</pub-id><pub-id pub-id-type="pmcid">PMC544101</pub-id></element-citation></ref><ref id="bb0320"><label>64.</label><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Pathogen recognition and development of particulate vaccines: does size matter?</article-title><source>Methods</source><volume>40</volume><year>2006</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16997708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymeth.2006.05.016</pub-id></element-citation></ref><ref id="bb0325"><label>65.</label><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><etal/></person-group><article-title>Exploiting lymphatic transport and complement activation in nanoparticle vaccines</article-title><source>Nat. Biotechnol.</source><volume>25</volume><year>2007</year><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">17873867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt1332</pub-id></element-citation></ref><ref id="bb0330"><label>66.</label><element-citation publication-type="journal" id="rf0330"><person-group person-group-type="author"><name name-style="western"><surname>Gutierro</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres</article-title><source>Vaccine</source><volume>21</volume><year>2002</year><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">12443664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(02)00435-8</pub-id></element-citation></ref><ref id="bb0335"><label>67.</label><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice</article-title><source>Pharm. Res.</source><volume>18</volume><year>2001</year><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">11442276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1011063232257</pub-id></element-citation></ref><ref id="bb0340"><label>68.</label><element-citation publication-type="journal" id="rf0340"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Re-considering how particle size and other properties of antigen-adjuvant complexes impact on the immune responses</article-title><source>J. Colloid Interface Sci.</source><volume>395</volume><year>2013</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">23312582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcis.2012.11.061</pub-id></element-citation></ref><ref id="bb0345"><label>69.</label><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name name-style="western"><surname>Monfardini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Veronese</surname><given-names>F.M.</given-names></name></person-group><article-title>Stabilization of substances in circulation</article-title><source>Bioconjug. Chem.</source><volume>9</volume><year>1998</year><fpage>418</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">9667945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bc970184f</pub-id></element-citation></ref><ref id="bb0350"><label>70.</label><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name name-style="western"><surname>Mumper</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Nanotemplate engineering of cell specific nanoparticles</article-title><source>J. Dispers. Sci. Technol.</source><volume>24</volume><year>2003</year><fpage>569</fpage><lpage>588</lpage></element-citation></ref><ref id="bb0355"><label>71.</label><element-citation publication-type="journal" id="rf0355"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy</article-title><source>Nanomedicine</source><volume>13</volume><year>2017</year><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">27520729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2016.07.015</pub-id><pub-id pub-id-type="pmcid">PMC5298946</pub-id></element-citation></ref><ref id="bb0360"><label>72.</label><element-citation publication-type="journal" id="rf0360"><person-group person-group-type="author"><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 &#916;V2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile <italic toggle="yes">Escherichia coli</italic> enterotoxin</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>1214</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">18243435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.12.030</pub-id></element-citation></ref><ref id="bb0365"><label>73.</label><element-citation publication-type="journal" id="rf0365"><person-group person-group-type="author"><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines</article-title><source>Curr. Drug Deliv.</source><volume>5</volume><year>2008</year><fpage>230</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">18855591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156720108785914961</pub-id></element-citation></ref><ref id="bb0370"><label>74.</label><element-citation publication-type="journal" id="rf0370"><person-group person-group-type="author"><name name-style="western"><surname>Kanchan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>A.K.</given-names></name></person-group><article-title>Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response</article-title><source>Biomaterials</source><volume>28</volume><year>2007</year><fpage>5344</fpage><lpage>5357</lpage><pub-id pub-id-type="pmid">17825905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2007.08.015</pub-id></element-citation></ref><ref id="bb0375"><label>75.</label><element-citation publication-type="journal" id="rf0375"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The current state of nanoparticle-induced macrophage polarization and reprogramming research</article-title><source>Int. J. Mol. Sci.</source><volume>18</volume><year>2017</year><fpage>336</fpage><pub-id pub-id-type="pmid">28178185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms18020336</pub-id><pub-id pub-id-type="pmcid">PMC5343871</pub-id></element-citation></ref><ref id="bb0380"><label>76.</label><element-citation publication-type="journal" id="rf0380"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stellacci</surname><given-names>F.</given-names></name></person-group><article-title>Effect of surface properties on nanoparticle-cell interactions</article-title><source>Small</source><volume>6</volume><year>2010</year><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">19844908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.200901158</pub-id></element-citation></ref><ref id="bb0385"><label>77.</label><element-citation publication-type="journal" id="rf0385"><person-group person-group-type="author"><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Induction of humoral and enhanced cellular immune responses by novel core&#8211;shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration</article-title><source>Vaccine</source><volume>27</volume><year>2009</year><fpage>3605</fpage><lpage>3615</lpage><pub-id pub-id-type="pmid">19464541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.03.047</pub-id></element-citation></ref><ref id="bb0390"><label>78.</label><element-citation publication-type="journal" id="rf0390"><person-group person-group-type="author"><name name-style="western"><surname>Mottram</surname><given-names>P.L.</given-names></name><etal/></person-group><article-title>Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus</article-title><source>Mol. Pharm.</source><volume>4</volume><year>2007</year><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">17274665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/mp060096p</pub-id></element-citation></ref><ref id="bb0395"><label>79.</label><element-citation publication-type="journal" id="rf0395"><person-group person-group-type="author"><name name-style="western"><surname>Fifis</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors</article-title><source>J. Immunol.</source><volume>173</volume><year>2004</year><fpage>3148</fpage><lpage>3154</lpage><pub-id pub-id-type="pmid">15322175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.173.5.3148</pub-id></element-citation></ref><ref id="bb0400"><label>80.</label><element-citation publication-type="journal" id="rf0400"><person-group person-group-type="author"><name name-style="western"><surname>Scheerlinck</surname><given-names>J.P.Y.</given-names></name><etal/></person-group><article-title>Systemic immune responses in sheep, induced by a novel nano-bead adjuvant</article-title><source>Vaccine</source><volume>24</volume><year>2006</year><fpage>1124</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">16202487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.09.009</pub-id></element-citation></ref><ref id="bb0405"><label>81.</label><element-citation publication-type="journal" id="rf0405"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>109</volume><year>2012</year><fpage>1080</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">22247289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1112648109</pub-id><pub-id pub-id-type="pmcid">PMC3268296</pub-id></element-citation></ref><ref id="bb0410"><label>82.</label><element-citation publication-type="journal" id="rf0410"><person-group person-group-type="author"><name name-style="western"><surname>Sneh-Edri</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro</article-title><source>Mol. Pharm.</source><volume>8</volume><year>2011</year><fpage>1266</fpage><lpage>1275</lpage><pub-id pub-id-type="pmid">21661745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/mp200198c</pub-id></element-citation></ref><ref id="bb0415"><label>83.</label><element-citation publication-type="journal" id="rf0415"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>J.F.S.</given-names></name><etal/></person-group><article-title>Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection</article-title><source>Vaccine</source><volume>27</volume><year>2009</year><fpage>3643</fpage><lpage>3649</lpage><pub-id pub-id-type="pmid">19464545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.03.040</pub-id></element-citation></ref><ref id="bb0420"><label>84.</label><element-citation publication-type="journal" id="rf0420"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><etal/></person-group><article-title>In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles</article-title><source>J. Control. Release</source><volume>112</volume><year>2006</year><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16529839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2006.01.006</pub-id></element-citation></ref><ref id="bb0425"><label>85.</label><element-citation publication-type="journal" id="rf0425"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>Y.W.</given-names></name><etal/></person-group><article-title>Near-infrared emitting polymer nanogels for efficient sentinel lymph node mapping</article-title><source>ACS Nano</source><volume>6</volume><year>2012</year><fpage>7820</fpage><lpage>7831</lpage><pub-id pub-id-type="pmid">22862428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn301949y</pub-id></element-citation></ref><ref id="bb0430"><label>86.</label><element-citation publication-type="journal" id="rf0430"><person-group person-group-type="author"><name name-style="western"><surname>Wilczewska</surname><given-names>A.Z.</given-names></name><etal/></person-group><article-title>Nanoparticles as drug delivery systems</article-title><source>Pharmacol. Rep.</source><volume>64</volume><year>2012</year><fpage>1020</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">23238461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1734-1140(12)70901-5</pub-id></element-citation></ref><ref id="bb0435"><label>87.</label><element-citation publication-type="journal" id="rf0435"><person-group person-group-type="author"><name name-style="western"><surname>Sloat</surname><given-names>B.R.</given-names></name><etal/></person-group><article-title>Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles</article-title><source>J. Control. Release</source><volume>141</volume><year>2010</year><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">19729045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2009.08.023</pub-id><pub-id pub-id-type="pmcid">PMC2789915</pub-id></element-citation></ref><ref id="bb0440"><label>88.</label><element-citation publication-type="journal" id="rf0440"><person-group person-group-type="author"><name name-style="western"><surname>Psimadas</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Molecular nanomedicine towards cancer</article-title><source>J. Pharm. Sci.</source><volume>101</volume><year>2012</year><fpage>2271</fpage><lpage>2280</lpage><pub-id pub-id-type="pmid">22488174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.23146</pub-id></element-citation></ref><ref id="bb0445"><label>89.</label><element-citation publication-type="journal" id="rf0445"><person-group person-group-type="author"><name name-style="western"><surname>Pati</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Nanoparticle vaccines against infectious diseases</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>2224</fpage><pub-id pub-id-type="pmid">30337923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02224</pub-id><pub-id pub-id-type="pmcid">PMC6180194</pub-id></element-citation></ref><ref id="bb0450"><label>90.</label><element-citation publication-type="journal" id="rf0450"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A simple self-adjuvanting biomimetic nanovaccine self-assembled with the conjugate of phospholipids and nucleotides can induce a strong cancer immunotherapeutic effect</article-title><source>Biomater. Sci.</source><volume>9</volume><year>2021</year><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">33016303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0bm01333a</pub-id></element-citation></ref><ref id="bb0455"><label>91.</label><element-citation publication-type="journal" id="rf0455"><person-group person-group-type="author"><name name-style="western"><surname>Kalkanidis</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity</article-title><source>Methods</source><volume>40</volume><year>2006</year><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">16997710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymeth.2006.05.018</pub-id></element-citation></ref><ref id="bb0460"><label>92.</label><element-citation publication-type="journal" id="rf0460"><person-group person-group-type="author"><name name-style="western"><surname>Zupan&#269;i&#269;</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming</article-title><source>J. Control. Release</source><volume>258</volume><year>2017</year><fpage>182</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">28511928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.05.014</pub-id></element-citation></ref><ref id="bb0465"><label>93.</label><element-citation publication-type="journal" id="rf0465"><person-group person-group-type="author"><name name-style="western"><surname>Means</surname><given-names>T.K.</given-names></name><etal/></person-group><article-title>The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells</article-title><source>J. Immunol.</source><volume>170</volume><year>2003</year><fpage>5165</fpage><lpage>5175</lpage><pub-id pub-id-type="pmid">12734364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.170.10.5165</pub-id></element-citation></ref><ref id="bb0470"><label>94.</label><element-citation publication-type="journal" id="rf0470"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5</article-title><source>Nature</source><volume>410</volume><year>2001</year><fpage>1099</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">11323673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35074106</pub-id></element-citation></ref><ref id="bb0475"><label>95.</label><element-citation publication-type="journal" id="rf0475"><person-group person-group-type="author"><name name-style="western"><surname>Hemmi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A Toll-like receptor recognizes bacterial DNA</article-title><source>Nature</source><volume>408</volume><year>2000</year><fpage>740</fpage><lpage>745</lpage><pub-id pub-id-type="pmid">11130078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35047123</pub-id></element-citation></ref><ref id="bb0480"><label>96.</label><element-citation publication-type="journal" id="rf0480"><person-group person-group-type="author"><name name-style="western"><surname>Di Marco</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation</article-title><source>Int. J. Nanomedicine</source><volume>5</volume><year>2010</year><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">20161986</pub-id><pub-id pub-id-type="pmcid">PMC2819905</pub-id></element-citation></ref><ref id="bb0485"><label>97.</label><element-citation publication-type="journal" id="rf0485"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>The impact of size on particulate vaccine adjuvants</article-title><source>Nanomedicine</source><volume>9</volume><year>2014</year><fpage>2671</fpage><lpage>2681</lpage><pub-id pub-id-type="pmid">25529570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/nnm.14.193</pub-id></element-citation></ref><ref id="bb0490"><label>98.</label><element-citation publication-type="journal" id="rf0490"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><etal/></person-group><article-title>New horizons in adjuvants for vaccine development</article-title><source>Trends Immunol.</source><volume>30</volume><year>2009</year><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">19059004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2008.09.006</pub-id></element-citation></ref><ref id="bb0495"><label>99.</label><element-citation publication-type="journal" id="rf0495"><person-group person-group-type="author"><name name-style="western"><surname>McDermott</surname><given-names>P.F.</given-names></name><etal/></person-group><article-title>High-affinity interaction between Gram-negative flagellin and a cell surface polypeptide results in human monocyte activation</article-title><source>Infect. Immun.</source><volume>68</volume><year>2000</year><fpage>5525</fpage><lpage>5529</lpage><pub-id pub-id-type="pmid">10992449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.68.10.5525-5529.2000</pub-id><pub-id pub-id-type="pmcid">PMC101501</pub-id></element-citation></ref><ref id="bb0500"><label>100.</label><element-citation publication-type="journal" id="rf0500"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines</article-title><source>J. Virol.</source><volume>75</volume><year>2001</year><fpage>9037</fpage><lpage>9043</lpage><pub-id pub-id-type="pmid">11533167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.75.19.9037-9043.2001</pub-id><pub-id pub-id-type="pmcid">PMC114472</pub-id></element-citation></ref><ref id="bb0505"><label>101.</label><element-citation publication-type="journal" id="rf0505"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Non-viral vector as vaccine carrier</article-title><source>Adv. Genet.</source><volume>54</volume><year>2005</year><fpage>315</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">16096017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0065-2660(05)54013-6</pub-id></element-citation></ref><ref id="bb0510"><label>102.</label><element-citation publication-type="journal" id="rf0510"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Non-viral vectors for gene-based therapy</article-title><source>Nat. Rev. Genet.</source><volume>15</volume><year>2014</year><fpage>541</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">25022906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg3763</pub-id></element-citation></ref><ref id="bb0515"><label>103.</label><element-citation publication-type="journal" id="rf0515"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy</article-title><source>Theranostics</source><volume>9</volume><year>2019</year><fpage>126</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">30662558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.29431</pub-id><pub-id pub-id-type="pmcid">PMC6332787</pub-id></element-citation></ref><ref id="bb0520"><label>104.</label><element-citation publication-type="journal" id="rf0520"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Dendrimer-like alpha-d-glucan nanoparticles activate dendritic cells and are effective vaccine adjuvants</article-title><source>J. Control. Release</source><volume>204</volume><year>2015</year><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">25747143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2015.03.002</pub-id></element-citation></ref><ref id="bb0525"><label>105.</label><element-citation publication-type="journal" id="rf0525"><person-group person-group-type="author"><name name-style="western"><surname>Gazi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Martinez-Pomares</surname><given-names>L.</given-names></name></person-group><article-title>Influence of the mannose receptor in host immune responses</article-title><source>Immunobiology</source><volume>214</volume><year>2009</year><fpage>554</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">19162368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2008.11.004</pub-id></element-citation></ref><ref id="bb0530"><label>106.</label><element-citation publication-type="journal" id="rf0530"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A trifunctional dextran-based nanovaccine targets and activates murine dendritic cells, and induces potent cellular and humoral immune responses in vivo</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e80904</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0080904</pub-id><pub-id pub-id-type="pmcid">PMC3855172</pub-id><pub-id pub-id-type="pmid">24339889</pub-id></element-citation></ref><ref id="bb0535"><label>107.</label><element-citation publication-type="journal" id="rf0535"><person-group person-group-type="author"><name name-style="western"><surname>Wamhoff</surname><given-names>E.C.</given-names></name><etal/></person-group><article-title>A specific, glycomimetic langerin ligand for human Langerhans cell targeting</article-title><source>ACS Cent. Sci.</source><volume>5</volume><year>2019</year><fpage>808</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">31139717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.9b00093</pub-id><pub-id pub-id-type="pmcid">PMC6535779</pub-id></element-citation></ref><ref id="bb0540"><label>108.</label><element-citation publication-type="journal" id="rf0540"><person-group person-group-type="author"><name name-style="western"><surname>Alloatti</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dendritic cell maturation and cross-presentation: timing matters!</article-title><source>Immunol. Rev.</source><volume>272</volume><year>2016</year><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">27319345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12432</pub-id><pub-id pub-id-type="pmcid">PMC6680313</pub-id></element-citation></ref><ref id="bb0545"><label>109.</label><element-citation publication-type="journal" id="rf0545"><person-group person-group-type="author"><name name-style="western"><surname>Embgenbroich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgdorf</surname><given-names>S.</given-names></name></person-group><article-title>Current concepts of antigen cross-presentation</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1643</fpage><pub-id pub-id-type="pmid">30061897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01643</pub-id><pub-id pub-id-type="pmcid">PMC6054923</pub-id></element-citation></ref><ref id="bb0550"><label>110.</label><element-citation publication-type="journal" id="rf0550"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Elastin blends for tissue engineering scaffolds</article-title><source>J. Biomed. Mater. Res. A</source><volume>79</volume><year>2006</year><fpage>963</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">16948146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jbm.a.30833</pub-id></element-citation></ref><ref id="bb0555"><label>111.</label><element-citation publication-type="journal" id="rf0555"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells</article-title><source>Biomacromolecules</source><volume>6</volume><year>2005</year><fpage>2590</fpage><lpage>2600</lpage><pub-id pub-id-type="pmid">16153096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bm0503221</pub-id></element-citation></ref><ref id="bb0560"><label>112.</label><element-citation publication-type="journal" id="rf0560"><person-group person-group-type="author"><name name-style="western"><surname>Zaric</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and th1 immune responses by murine langerhans cells</article-title><source>J. Invest. Dermatol.</source><volume>135</volume><year>2015</year><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">25243789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2014.415</pub-id></element-citation></ref><ref id="bb0565"><label>113.</label><element-citation publication-type="journal" id="rf0565"><person-group person-group-type="author"><name name-style="western"><surname>Hirosue</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation</article-title><source>Vaccine</source><volume>28</volume><year>2010</year><fpage>7897</fpage><lpage>7906</lpage><pub-id pub-id-type="pmid">20934457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.09.077</pub-id></element-citation></ref><ref id="bb0570"><label>114.</label><element-citation publication-type="journal" id="rf0570"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens</article-title><source>eLife</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">e57659</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.57659</pub-id><pub-id pub-id-type="pmcid">PMC7402677</pub-id><pub-id pub-id-type="pmid">32748788</pub-id></element-citation></ref><ref id="bb0575"><label>115.</label><element-citation publication-type="journal" id="rf0575"><person-group person-group-type="author"><name name-style="western"><surname>Sixt</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node</article-title><source>Immunity</source><volume>22</volume><year>2005</year><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">15664156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2004.11.013</pub-id></element-citation></ref><ref id="bb0580"><label>116.</label><element-citation publication-type="journal" id="rf0580"><person-group person-group-type="author"><name name-style="western"><surname>Theodoras</surname><given-names>J.</given-names></name></person-group><article-title>Timing is everything</article-title><source>Lightwave</source><volume>28</volume><year>2011</year><fpage>23</fpage><lpage>29</lpage></element-citation></ref><ref id="bb0585"><label>117.</label><element-citation publication-type="journal" id="rf0585"><person-group person-group-type="author"><name name-style="western"><surname>Copland</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Liposomal delivery of antigen to human dendritic cells</article-title><source>Vaccine</source><volume>21</volume><year>2003</year><fpage>883</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">12547598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(02)00536-4</pub-id></element-citation></ref><ref id="bb0590"><label>118.</label><element-citation publication-type="journal" id="rf0590"><person-group person-group-type="author"><name name-style="western"><surname>Van Broekhoven</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy</article-title><source>Cancer Res.</source><volume>64</volume><year>2004</year><fpage>4357</fpage><lpage>4365</lpage><pub-id pub-id-type="pmid">15205352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-04-0138</pub-id></element-citation></ref><ref id="bb0595"><label>119.</label><element-citation publication-type="journal" id="rf0595"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.S.-Y.Y.</given-names></name><etal/></person-group><article-title>Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity</article-title><source>Biomaterials</source><volume>130</volume><year>2017</year><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">28364631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2017.03.034</pub-id></element-citation></ref><ref id="bb0600"><label>120.</label><element-citation publication-type="journal" id="rf0600"><person-group person-group-type="author"><name name-style="western"><surname>Manolova</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Nanoparticles target distinct dendritic cell populations according to their size</article-title><source>Eur. J. Immunol.</source><volume>38</volume><year>2008</year><fpage>1404</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">18389478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.200737984</pub-id></element-citation></ref><ref id="bb0605"><label>121.</label><element-citation publication-type="journal" id="rf0605"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>G.P.</given-names></name><etal/></person-group><article-title>Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration</article-title><source>Nano Res.</source><volume>12</volume><year>2019</year><fpage>837</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">33343832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12274-019-2301-3</pub-id><pub-id pub-id-type="pmcid">PMC7747954</pub-id></element-citation></ref><ref id="bb0610"><label>122.</label><element-citation publication-type="journal" id="rf0610"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Modulating antibacterial immunity via bacterial membrane-coated nanoparticles</article-title><source>Nano Lett.</source><volume>15</volume><year>2015</year><fpage>1403</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">25615236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nl504798g</pub-id><pub-id pub-id-type="pmcid">PMC4399974</pub-id></element-citation></ref><ref id="bb0615"><label>123.</label><element-citation publication-type="journal" id="rf0615"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Biocompatible chitosan nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce potent cytokines and antibody response through activation of &#947;&#948; T cells in mice</article-title><source>Nanotechnology</source><volume>28</volume><year>2017</year><object-id pub-id-type="publisher-id">165101</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/1361-6528/aa60fd</pub-id><pub-id pub-id-type="pmid">28206982</pub-id></element-citation></ref><ref id="bb0620"><label>124.</label><element-citation publication-type="journal" id="rf0620"><person-group person-group-type="author"><name name-style="western"><surname>Climent</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses</article-title><source>Nanomedicine</source><volume>14</volume><year>2018</year><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">29157976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2017.11.009</pub-id></element-citation></ref><ref id="bb0625"><label>125.</label><element-citation publication-type="journal" id="rf0625"><person-group person-group-type="author"><name name-style="western"><surname>Kodali</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Dysregulation of macrophage activation profiles by engineered nanoparticles</article-title><source>ACS Nano</source><volume>7</volume><year>2013</year><fpage>6997</fpage><lpage>7010</lpage><pub-id pub-id-type="pmid">23808590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn402145t</pub-id><pub-id pub-id-type="pmcid">PMC3756554</pub-id></element-citation></ref><ref id="bb0630"><label>126.</label><element-citation publication-type="journal" id="rf0630"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X.-Q.</given-names></name><etal/></person-group><article-title>A20&#8211;OVA nanoparticles inhibit allergic asthma in a murine model</article-title><source>Inflammation</source><volume>43</volume><year>2020</year><fpage>953</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">31938979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-020-01181-5</pub-id></element-citation></ref><ref id="bb0635"><label>127.</label><element-citation publication-type="journal" id="rf0635"><person-group person-group-type="author"><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name></person-group><article-title>Overview of the IL-1 family in innate inflammation and acquired immunity</article-title><source>Immunol. Rev.</source><volume>281</volume><year>2018</year><fpage>8</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">29247995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12621</pub-id><pub-id pub-id-type="pmcid">PMC5756628</pub-id></element-citation></ref><ref id="bb0640"><label>128.</label><element-citation publication-type="journal" id="rf0640"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>DNA&#8211;inorganic hybrid nanovaccine for cancer immunotherapy</article-title><source>Nanoscale</source><volume>8</volume><year>2016</year><fpage>6684</fpage><lpage>6692</lpage><pub-id pub-id-type="pmid">26947116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c5nr08821f</pub-id><pub-id pub-id-type="pmcid">PMC4807396</pub-id></element-citation></ref><ref id="bb0645"><label>129.</label><element-citation publication-type="journal" id="rf0645"><person-group person-group-type="author"><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma</article-title><source>Proc. Natl. Acad. Sci.</source><volume>93</volume><year>1996</year><fpage>2879</fpage><lpage>2883</lpage><pub-id pub-id-type="pmid">8610135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.93.7.2879</pub-id><pub-id pub-id-type="pmcid">PMC39727</pub-id></element-citation></ref><ref id="bb0650"><label>130.</label><element-citation publication-type="journal" id="rf0650"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>Therapeutic potential of Toll-like receptor 9 activation</article-title><source>Nat. Rev. Drug Discov.</source><volume>5</volume><year>2006</year><fpage>471</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">16763660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2059</pub-id></element-citation></ref><ref id="bb0655"><label>131.</label><element-citation publication-type="journal" id="rf0655"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Pathogen recognition by the innate immune system</article-title><source>Int. Rev. Immunol.</source><volume>30</volume><year>2011</year><fpage>16</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">21235323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/08830185.2010.529976</pub-id></element-citation></ref><ref id="bb0660"><label>132.</label><element-citation publication-type="journal" id="rf0660"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours</article-title><source>Adv. Healthc. Mater.</source><volume>3</volume><year>2014</year><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">24520022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201300525</pub-id></element-citation></ref><ref id="bb0665"><label>133.</label><element-citation publication-type="journal" id="rf0665"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>N.-L.L.</given-names></name><etal/></person-group><article-title>A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation</article-title><source>J. Immunol.</source><volume>183</volume><year>2009</year><fpage>2337</fpage><lpage>2348</lpage><pub-id pub-id-type="pmid">19635915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0901203</pub-id><pub-id pub-id-type="pmcid">PMC2786780</pub-id></element-citation></ref><ref id="bb0670"><label>134.</label><element-citation publication-type="journal" id="rf0670"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells</article-title><source>Int. J. Nanomedicine</source><volume>13</volume><year>2018</year><fpage>3353</fpage><lpage>3365</lpage><pub-id pub-id-type="pmid">29922056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S164097</pub-id><pub-id pub-id-type="pmcid">PMC5995426</pub-id></element-citation></ref><ref id="bb0675"><label>135.</label><element-citation publication-type="journal" id="rf0675"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>L.R.</given-names></name><etal/></person-group><article-title>Phase I clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin</article-title><source>Vaccine</source><volume>28</volume><year>2010</year><fpage>2565</fpage><lpage>2572</lpage><pub-id pub-id-type="pmid">20117262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.01.029</pub-id></element-citation></ref><ref id="bb0680"><label>136.</label><element-citation publication-type="journal" id="rf0680"><person-group person-group-type="author"><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>I.C.</given-names></name></person-group><article-title>New technology platforms in the development of vaccines for the future</article-title><source>Vaccine</source><volume>20</volume><year>2002</year><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(02)00513-3</pub-id><pub-id pub-id-type="pmid">12477412</pub-id></element-citation></ref><ref id="bb0685"><label>137.</label><element-citation publication-type="journal" id="rf0685"><person-group person-group-type="author"><name name-style="western"><surname>Bradbury</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>F.A.</given-names></name></person-group><article-title>Immunotherapy for lung cancer</article-title><source>J. Thorac. Oncol.</source><volume>3</volume><year>2008</year><fpage>164</fpage><lpage>170</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0b013e318174e9a7</pub-id><pub-id pub-id-type="pmid">18520304</pub-id></element-citation></ref><ref id="bb0690"><label>138.</label><element-citation publication-type="journal" id="rf0690"><person-group person-group-type="author"><name name-style="western"><surname>Bovier</surname><given-names>P.A.</given-names></name></person-group><article-title>Epaxal&#174;: a virosomal vaccine to prevent hepatitis A infection</article-title><source>Expert Rev. Vaccines</source><volume>7</volume><year>2008</year><fpage>1141</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">18844588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.7.8.1141</pub-id></element-citation></ref><ref id="bb0695"><label>139.</label><element-citation publication-type="journal" id="rf0695"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">32756549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmcid">PMC7581537</pub-id></element-citation></ref><ref id="bb0700"><label>140.</label><element-citation publication-type="journal" id="rf0700"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>An mRNA vaccine against SARS-CoV-2 &#8211; preliminary report</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></element-citation></ref><ref id="bb0705"><label>141.</label><element-citation publication-type="journal" id="rf0705"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">32785213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id></element-citation></ref><ref id="bb0710"><label>142.</label><element-citation publication-type="journal" id="rf0710"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="bb0715"><label>143.</label><element-citation publication-type="journal" id="rf0715"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J.-H.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title><source>Nat. Commun.</source><volume>12</volume><year>2021</year><fpage>372</fpage><pub-id pub-id-type="pmid">33446655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmcid">PMC7809486</pub-id></element-citation></ref><ref id="bb0720"><label>144.</label><element-citation publication-type="journal" id="rf0720"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>936</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">32801356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-00392-7</pub-id><pub-id pub-id-type="pmcid">PMC7429369</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0050"><title>Acknowledgments</title><p id="p0230">M.A., A.S., H.K.P., and J.H. acknowledge the Medical Inflammation and Infection Center (MIIC) at Link&#246;ping University, Sweden, for international postdoctoral funding for nanovaccine research. H.K.P. has been supported by an EU <funding-source id="gts0005">Horizon 2020 Marie Sk&#322;odowska-Curie Fellowship</funding-source> (grant 706694) and a <funding-source id="gts0010">UK Medical Research Council Career Development Award</funding-source> (MR/T030968/1). H.K.P., G.H.Z. and N.K.H.S. thank the British Council, the UK&#8211;India Education and Research Initiative (<funding-source id="gts0015"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000732</institution-id><institution>UKIERI</institution></institution-wrap></funding-source>), and the <funding-source id="gts0020">Government of India</funding-source> for grant P325 under the Scheme for Promotion of Academic and Research Collaboration (SPARC) program. We thank Dr Tuhin Subhra Sarkar from the Sister Nibedita Government General Degree College for Girls (India) and Dr Alexandru Chivu (The Patra Laboratory of H.K.P.) who helped to translate our ideas into scientific illustrations (created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://BioRender.com" id="ir0015">BioRender.com</ext-link>).</p></sec><sec sec-type="COI-statement" id="s0055"><title>Declaration of interests</title><p id="p0235">The authors declare no conflicts of interest.</p></sec></ack></back></article></pmc-articleset>